

CURRICULUM VITAE

NIMISH PATEL, PHARM.D., PH.D.

Table of Contents

CURRENT POSITION	2
PREVIOUS POSITIONS	2
ACADEMIC & CLINICAL PHARMACY PRACTICE SITES	2
PHARMACIST LICENSURE	3
GRADUATE EDUCATION	3
POSTGRADUATE TRAINING	3
ADVANCED COURSEWORK	4
SCHOLARLY ACTIVITY	5
PUBLISHED ORIGINAL RESEARCH (PEER-REVIEWED)	5
PUBLISHED ORIGINAL RESEARCH (IN PROGRESS)	12
REVIEW ARTICLES	12
BOOK CHAPTERS	13
PUBLISHED ABSTRACTS	13
INVITED PRESENTATIONS	25
RESEARCH GRANTS	29
GRANTS - AWARDED	29
GRANTS – UNFUNDED/AWAITING DECISION	34
TEACHING EXPERIENCE	40
UNIVERSITY OF CALIFORNIA, SAN DIEGO; SKAGGS SCHOOL OF PHARMACY & PHARMACEUTICAL SCIENCES (LA JOLLA, CALIFORNIA)	40
ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES (ALBANY, NEW YORK)	42
STATE UNIVERSITY OF NEW YORK, UNIVERSITY ALBANY, SCHOOL OF PUBLIC HEALTH (ALBANY, NEW YORK) ..	53
STRATTON VETERANS AFFAIRS MEDICAL CENTER (ALBANY, NEW YORK)	53
PROFESSIONAL SERVICE RESPONSIBILITIES	54
UNIVERSITY OF CALIFORNIA SAN DIEGO – SKAGGS SCHOOL OF PHARMACY & PHARMACEUTICAL SCIENCES	54
SERVICE – INTRAMURAL	54
SERVICE – EXTRAMURAL, LEADERSHIP POSITIONS IN PROFESSIONAL SOCIETIES	54
ALBANY COLLEGE OF PHARMACY & HEALTH SCIENCES	55
SERVICE – INTRAMURAL	55
SERVICE – EXTRAMURAL, LEADERSHIP POSITIONS IN PROFESSIONAL SOCIETIES	56
SERVICE – EXTRAMURAL, PEER REVIEWER FOR JOURNALS	57
CERTIFICATIONS AND TRAINING	60
HONORS AND AWARDS	60
PROFESSIONAL ORGANIZATIONS	61

CURRENT POSITION

7/2022 – present **Professor of Clinical Pharmacy**
Skaggs School of Pharmacy & Pharmaceutical Sciences
University of California San Diego (UCSD)
Division of Clinical Pharmacy
9500 Gilman Drive, MC 0657
La Jolla, CA 92093-0657
Phone: 858-822-3561; E-mail: nipatel@health.ucsd.edu

PREVIOUS POSITIONS

10/2018 – 6/2022 **Associate Professor of Clinical Pharmacy**
Skaggs School of Pharmacy & Pharmaceutical Sciences, UCSD
Division of Clinical Pharmacy

7/2016 – 10/2018 **Associate Professor**
Albany College of Pharmacy and Health Sciences
Department of Pharmacy Practice

9/2015 – 10/2018 **Per Diem Pharmacist**
Albany Medical Center

7/2010 – 6/2016 **Assistant Professor**
Albany College of Pharmacy and Health Sciences
Department of Pharmacy Practice

5/2006 – 6/2010 **Per Diem Pharmacist**
Rite Aid Pharmacy

ACADEMIC & CLINICAL PHARMACY PRACTICE SITES

2020 – present **Antiviral Research Center; UCSD, San Diego, CA**
Role: Investigational Drug Service Pharmacist

2021 – present **Student Health Services; UCSD, San Diego, CA**
Role: Pre-Exposure Prophylaxis (PrEP) Pharmacist

2015 – 2018 **HIV/HCV Coinfection Clinic; Stratton VA, Albany, NY**
Role: Clinical Pharmacist

- 2010 – 2018 **Pharmacokinetic Monitoring Service and Infectious Diseases Stewardship Program; Stratton VA, Albany, NY**
Role: Clinical Pharmacist
- 2009 – 2010 **HIV Consult Service; Albany Medical Center, Albany, NY**
Role: Clinical Pharmacist

PHARMACIST LICENSURE

- 2020 – present **State of California**
Registered Pharmacist #82140
- 2010 – present **State of New York**
Registered Pharmacist #20-055292
- 2009 – present **Commonwealth of Massachusetts**
Pharmacist License #PH232421
- 2006 – 2009 **State of New York**
Registered Pharmacist Limited License # 000202

GRADUATE EDUCATION

- 2010 – 2014 **Doctor of Philosophy, Epidemiology**
State University of New York, School of Public Health
Albany, New York
- 2007 – 2009 **Masters of Science, Epidemiology**
State University of New York, School of Public Health
Albany, New York
- 2000 – 2006 **Doctor of Pharmacy (PharmD)**
Albany College of Pharmacy and Health Sciences
Albany, New York

Postgraduate Training

- 2007-2010 **Infectious Diseases Outcomes Fellowship**
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York

2006-2007

HIV Specialty Pharmacy Resident

University Health Network – Toronto General Hospital
McGill University Health Centre – L’Institut Thoracique

Advanced Coursework

2007-2014

State University of New York, School of Public Health

Survivorship Analyses (HSTA 666)

Clinical Trials (HSTA 656)

Infectious Diseases Epidemiology (HEPI 605)

Categorical Data Analysis (HSTA 556, audit)

Field Placement (HEPI 690)

Topics in Epidemiology (HEPI 601)

Master’s Thesis (HEPI 699)

Principles and Methods of Epidemiology I (HEPI 501)

Principles and Methods of Epidemiology II (HEPI 502)

Principles of Public Health (EPI 503)

Principles of Statistical Inference I (HSTA 552)

Principles of Statistical Inference II (HSTA 553)

Quantitative Methods in Epidemiology (HEPI 612)

Computer Programming for Data Mgmt & Analysis (HEPI 514)

Master’s Seminar in Epidemiology (HEPI 602)

Advanced Infectious Diseases Seminar Epidemiology (HEPI 631)

Introduction to Bioinformatics (HSTA 697)

Vaccine Epidemiology (HEPI 512)

Independent Research Study (HEPI 897)

AIDS Epidemiology (HEPI 610)

Published Original Research (peer-reviewed)

*Denotes work completed as a faculty member

*Berenbrok LA, Tang S, Gabriel N, Guo J, Sharareh N, **Patel N**, Dickson S, Hernandez I. Access to community pharmacies: A nationwide geographic information systems cross-sectional analysis. *J Am Pharm Assoc* (2003). 2022 Jul 15:S1544-3191(22)00233-3. doi: 10.1016/j.japh.2022.07.003. Epub ahead of print. PMID: 35965233.

*Veve MP, Mercurio NJ, Sangiovanni RJ, Santarossa M, **Patel N**. Prevalence and Predictors of *Pseudomonas aeruginosa* Among Hospitalized Patients With Diabetic Foot Infections. *Open Forum Infect Dis*. 2022 Jun 17;9(7):ofac297. doi: 10.1093/ofid/ofac297. PMID: 35873292; PMCID: PMC9301575.

***Patel N**, Blumenthal J, Dubé MP, Hood A, Bolan R, Morris S. Method of Calculating Renal Function Estimates Could Inappropriately Exclude Transgender Patients Receiving Gender-Affirming Hormone Therapy from Pre-Exposure Prophylaxis Eligibility. *LGBT Health*. 2022 Feb 23. doi: 10.1089/lgbt.2021.0219. Epub ahead of print. PMID: 35196473.

*On S, Rath CG, Lan M, Wu B, Lau KM, Cheung E, Alegria W, Young R, Tan M, Kim C, Phun J, **Patel N**, Mannis G, Logan AC, Kennedy V, Goodman A, Taplitz RA, Young PA, Wen R, Saunders IM. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent. *Br J Haematol*. 2022 Feb 16. doi: 10.1111/bjh.18051. Epub ahead of print. PMID: 35174480.

Wagner JL, Boyle J, Boyle CJ, Choi D, Ballou JM, **Patel N**, Persky AM, Malcom DR. Overcoming Past Perceptions and Profession-Wide Identity Crisis to Reflect Pharmacy's Future. *Am J Pharm Educ*. 2021 Nov 16:8829. doi: 10.5688/ajpe8829. Epub ahead of print. PMID: 34785501.

Lodise T, Rodriguez M, Chitra S, Wright K, **Patel N**. Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for *Clostridioides difficile* Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective. *Antibiotics (Basel)*. 2021 Oct 1;10(10):1195. doi: 10.3390/antibiotics10101195. PMID: 34680776; PMCID: PMC8532985.

*Lodise TP, Henriksen AS, Hadley T, **Patel N**. US-Focused Conceptual Health Care Decision-Analytic Models Examining the Value of Pivmecillinam Relative to Current Standard-of-Care Agents Among Adult Patients With Uncomplicated Urinary Tract Infections due to *Enterobacterales*. *Open Forum Infect Dis*. 2021 Oct 15;8(10):ofab380. doi: 10.1093/ofid/ofab380. PMID: 34660834; PMCID: PMC8516593.

*Salama E, Hill L, **Patel N**, Best BM, Momper JD. Pharmacokinetics of bictegavir and tenofovir in combination with darunavir/cobicistat in treatment-experienced persons with HIV. *J Acquir Immune Defic Syndr*. 2021 Jul 19. doi: 10.1097/QAI.0000000000002765. Epub ahead of print. PMID: 34285156.

***Patel N**, Lowry C, Morgenson D, Shah V, Stornelli N, Lodise TP. Comparative effectiveness of early-targeted use of fidaxomicin versus oral vancomycin among hospitalized veterans' affairs patients with infections due to *Clostridioides difficile*. *Pharmacotherapy*. 2021 Feb;41(2):212-219. doi: 10.1002/phar.2503. Epub 2021 Feb 8. PMID: 33455007.

*Veve MP, **Patel N**, Smith ZA, Yeager SD, Wright LR, Shorman MA. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections. *Int J Antimicrob Agents*. 2020 Dec;56(6):106210. doi: 10.1016/j.ijantimicag.2020.106210. Epub 2020 Oct 23. PMID: 33223119.

*Adams JL, Murray M, **Patel N**, Sawkin MT, Boardman RC, Pham C, Kaur H, Patel D, Yager JL, Pontiggia L, Baxter J. Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study. *HIV Med*. 2021 Jan;22(1):28-36. doi: 10.1111/hiv.12959. Epub 2020 Sep 23. PMID: 32964664.

*Cooksey GE, Epps JL, Moyer RA, **Patel N**, Shorman MA, Veve MP. Impact of a Plan of Care Protocol on Patient Outcomes in People Who Inject Drugs With Infective Endocarditis. *J Infect Dis*. 2020;222(Supplement_5):S506-S512. doi:10.1093/infdis/jiaa055

***Patel N**, Stornelli N, Sangiovanni RJ, Huang DB, Lodise TP. Effect of Vancomycin-Associated Acute Kidney Injury on Incidence of 30-Day Readmissions among Hospitalized Veterans Affairs Patients with Skin and Skin Structure Infections. *Antimicrob Agents Chemother*. 2020 Sep 21;64(10):e01268-20. doi: 10.1128/AAC.01268-20. PMID: 32718970; PMCID: PMC7508587.

*Maskarinec SA, Park LP, Ruffin F, Turner NA, **Patel N**, Eichenberger EM, van Duin D, Lodise T, Fowler VG Jr, Thaden JT. Positive follow-up blood cultures identify high

mortality risk among patients with Gram-negative bacteraemia. *Clin Microbiol Infect.* 2020 Jul;26(7):904-910. doi: 10.1016/j.cmi.2020.01.025. Epub 2020 Feb 28.

*Ahmed A, Schriever C, Britt NS, Yager JL, Amin R, McGuey L, **Patel N**. Comparing Drug Interaction Frequencies of Various Hepatitis C Treatment Regimens among Monoinfected Patients. *Ann Hepatol.* 2019 Jul-Aug;18(4):601-606. doi: 10.1016/j.aohep.2019.01.005. Epub 2019 May 4.

*Sangiovanni R, Jakeman BJ, Nasiri M, Ruth L, Mahatme S, **Patel N**. Relationship between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations among HIV-infected Patients Initiating Combination Antiretroviral Therapy. *AIDS Res Hum Retroviruses.* 2019 May;35(5):430-433. doi: 10.1089/AID.2018.0205. Epub 2019 Feb 27.

***Patel N**, Huang D, Lodise T. Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. *Clin Drug Investig.* 2018 Oct;38(10):935-943. doi: 10.1007/s40261-018-0686-5.

*Bidell MR, **Patel N**, O'Donnell JN. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. *J Antimicrob Chemother.* 2018 Oct 1;73(10):2643-2651. doi: 10.1093/jac/dky259.

***Patel N**, Borg P, Haubrich R, McNicholl I. Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. *Am J Health Syst Pharm.* 2018 Aug 1;75(15):1132-1139. doi: 10.2146/ajhp170613. Epub 2018 Jun 14.

*Terloyeva D, Nugmanova Z, Akhmetova GM, Akanov AA, **Patel N**, Lazariu V, Norelli L, McNutt LA. Untreated Depression among Persons Living with Human Immunodeficiency Virus in Kazakhstan: a Cross-Sectional Study. *PLoS One.* 2018 Mar 28;13(3):e0193976. doi: 10.1371/journal.pone.0193976. eCollection 2018.

*Landry S, Chen CN, **Patel N**, Tseng A, Lalonde R, Thibault D, Sheehan N. Therapeutic Drug Monitoring in Treatment-Experienced HIV-Infected Patients Receiving Darunavir-Based Salvage Regimens: A Case Series. *Antiviral Res.* 2018 Apr;152:111-116. doi: 10.1016/j.antiviral.2018.02.010. Epub 2018 Feb 17.

*Yager J, Faragon J, McGuey L, Hoye-Simek A, Hecox Z, Sullivan S, Neubert S, **Patel N**. Relationship between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications among Veterans' Affairs Patients

with Human Immunodeficiency Virus. *AIDS Patient Care STDS*. 2017 Sep;31(9):370-376. doi: 10.1089/apc.2017.0081. Epub 2017 Aug 3.

*Britt NS, Potter EM, McKinnell JA, **Patel N**, Battersby SE, Steed ME. Secular trends in nosocomial vancomycin-resistant enterococcal bloodstream infections among United States Veterans Affairs hospitals, fiscal years 2004-2014. *Infect Control Hosp Epidemiol*. 2017 Jul 11:1-3. doi: 10.1017/ice.2017.125. [Epub ahead of print].

*Malek W, Yager J, Britt NS, Morse C, Hecox Z, Hoye-Simek A, Sullivan S, **Patel N**. Clinical Outcomes Associated with Single Tablet Regimens: Relationship between Antiretroviral Therapy Pill Burden and Control of Concomitant Comorbidities among HIV-infected Patients. *Journal of HIV and Retrovirus*. 2017 June;3(1:5):1-7.

*Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, **Patel N**. Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients. *Ann Pharmacother*. 2017 May;51(5):365-372. doi: 10.1177/1060028016685115. Epub 2016 Dec 20.

*Britt NS, Potter EM, **Patel N**, Steed ME. Effect of Continuous and Sequential Therapy Among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant *Enterococcus faecium* Bacteremia. *Antimicrob Agents Chemother*. 2017 Apr 24;61(5). pii: e02216-16. doi: 10.1128/AAC.02216-16. Print 2017 May.

*Britt NS, Potter EM, **Patel N**, Steed ME. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. *Clin Infect Dis*. 2017 Mar 1;64(5):605-613. doi: 10.1093/cid/ciw815.

*Britt NS, **Patel N**, Shireman TI, El Atrouni WI, Horvat RT, Steed ME. Relationship between vancomycin tolerance and clinical outcomes in *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother*. 2016 Dec 20. pii: dkw453. doi: 10.1093/jac/dkw453. [Epub ahead of print].

*Britt NS, **Patel N**, Horvat RT, Steed ME. Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant *Staphylococcus aureus* Bacteremia. *Antimicrob Agents Chemother*. 2016 Apr 22;60(5):3070-5. doi: 10.1128/AAC.02714-15. Print 2016 May.

*Nugmanova Z, **Patel N**, Akhmetova GM, Kurmangalieva GS, Abdumananova MK, Akanov AA, Kovtunenkov NG, McNutt LA. Relationship between vitamin D and human immunodeficiency virus (HIV) viral load among HIV-infected patients in Kazakhstan. *J Infect Dev Ctries*. 2015 Nov 30;9(11):1277-83. doi: 10.3855/jidc.6808

- ***Patel N**, Assimon M, Bruni E, McNutt LA, Mason DL. Incidence and Clinical Predictors of Non-Response to Hepatitis B Vaccination among Patients Receiving Hemodialysis: Importance of Obesity. *South Med J*. 2015 Sep;108(9):567-73. doi: 10.14423/SMJ.0000000000000343.
- *Britt NS, Potter EM, **Patel N**, Steed ME. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. *Clin Infect Dis*. 2015 Sep 15;61(6):871-8. doi: 10.1093/cid/civ444. Epub 2015 Jun 10.
- ***Patel N**, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, Miller CD. Comparing the Frequency of Drug Interactions after Adding Simeprevir- or Sofosbuvir-containing therapy to Medication Profiles of Hepatitis C Monoinfected Patients: A Quantitative Analysis to Aid in Selecting Therapy. *Infect Dis Ther*. 2015 Jan 28. [Epub ahead of print].
- *Nugmanova Z, **Patel N**, Nurbakhyt A, Akhmetova GM, Kovtunenکو NS, Trumova Z, McNutt LA. Universal precautions in Central Asia: the need for multiple strategies in this window of opportunity. *J Hosp Infect*. 2015 Mar;89(3):197-201. doi: 10.1016/j.jhin.2014.11.011. Epub 2014 Dec 24.
- ***Patel N**, Nasiri M, Koroglu A, Amin R, McGuey L, McNutt LA, Roman M, Miller CD. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment among HIV and hepatitis C coinfecting patients. *AIDS Res Hum Retroviruses*. 2015 Feb;31(2):189-97. doi: 10.1089/AID.2014.0215. Epub 2015 Jan 6.
- *McConnell HL, Perris ET, Lowry C, Lodise T, **Patel N**. Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. *Infect Dis Ther*. 2014 Sep 23. [Epub ahead of print]
- ***Patel N**, Veve M, Nasiri M, Bliss S, McNutt LA, Lazariu V, Miller C. Predicting the Probability of Experiencing Clinically Significant Drug-Drug Interactions Involving Boceprevir-Containing Hepatitis C Therapy Among Patients Coinfected with Hepatitis C and HIV. *AIDS Patient Care STDS*. 2014 Oct;28(10):513-6. doi: 10.1089/apc.2014.0149. Epub 2014 Aug 5.
- ***Patel N**, Veve MP, Bliss S, Nasiri M, McNutt LA, Lazariu V, Roman M, Miller CD. Prevalence and predictors of important telaprevir drug interactions among patients co-infected with hepatitis C and human immunodeficiency virus. *J Pharm Technol*. 2014 October: 159-167. doi: 10.1177/8755122514533941.

*Lodise TP, **Patel N**, Rivera A, Tristani L, Lazariu V, Vandewall H, McNutt LA. Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin. *Antimicrob Agents Chemother*. 2013 Dec;57(12):5901-11. doi: 10.1128/AAC.00921-13. Epub 2013 Sep 16.

Casapao AM, Leonard SN, Davis SL, Lodise TP, **Patel N**, Goff DA, Laplante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate *Staphylococcus aureus* (hVISA) bloodstream infection. *Antimicrob Agents Chemother*. 2013 Jun 24. [Epub ahead of print]

***Patel N**, Veve M, Kwon S, McNutt LA, Fish D, Miller C. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation. *HIV Med*. 2013 Sep;14(8):463-71. doi: 10.1111/hiv.12031. Epub 2013 Mar 18.

*Butterfield JM, Mueller B, **Patel N**, Cardone K, Grabe DW, Salama N, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis. *Antimicrob Agents Chemother*. 2013 Feb;57(2):864-72. doi: 10.1128/AAC.02000-12. Epub 2012 Dec 3.

*Miller S, **Patel N**, Vadala T, Abrons J, Cerulli J. Defining the pharmacist role in the pandemic outbreak of novel H1N1 influenza. *J Am Pharm Assoc (2003)*. 2012 Nov 1;52(6):763-7. doi: 10.1331/JAPhA.2012.11003.

Patel N, VanDeWall H, Tristani L, Rivera A, Woo B, Dihmess A, Li HK, Smith R, Lodise TP. A Comparative Evaluation of Adverse Platelet Outcomes among Veterans' Affairs Patients Receiving Linezolid and Vancomycin. *J Antimicrob Chemother*. 2012 Mar;67(3):727-35. Epub 2011 Dec 15.

*Butterfield J, **Patel N**, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors that Influence Protein Binding. *Antimicrob Agents Chemother*. 2011 Sep;55(9):4277-82. Epub 2011 Jun 13.

Patel N, Harrington S, Dihmess A, Woo B, Masoud R, Martis P, Fiorenza M, Graffunder E, Evans A, McNutt LA, Lodise TP. Clinical epidemiology of carbapenem-intermediate or -resistant Enterobacteriaceae. *J Antimicrob Chemother*. 2011 Jul;66(7):1600-8. Epub 2011 Apr 19.

Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: We Can't Get There from Here. *Clin Infect Dis*. 2011 Apr;52(8):969-74.

Cardone KE, Lodise TP, **Patel N**, Hoy CD, Meola S, Manley HJ, Drusano GL, Grabe DW. Pharmacokinetics and Pharmacodynamics of Intravenous Daptomycin during Continuous Ambulatory Peritoneal Dialysis. *Clin J Am Soc Nephrol*. 2011 May;6(5):1081-8. Epub 2011 Mar 10.

***Patel N**, Abdelsayed S, Veve M, Miller CD. Predictors of Clinically Significant Drug-Drug Interactions among Patients Treated with Non-nucleoside Reverse Transcriptase inhibitor-, Protease Inhibitor-, and Raltegravir-based Antiretroviral Regimens. *Ann Pharmacother*. 2011 Mar;45(3):317-24. Epub 2011 Mar 8.

Patel N, Cardone K, Grabe DW, Meola S, Hoy C, Manley H, Drusano GL, Lodise TP. Use of Pharmacokinetic and Pharmacodynamic Principles to Determine Optimal Administration of Daptomycin in Patients Receiving Standardized Thrice Weekly Hemodialysis. *Antimicrob Agents Chemother*. 2011 Apr;55(4):1677-83. Epub 2011 Jan 31.

Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of Optimal Renal Dosage Adjustments for Traditional and Extended Infusion Piperacillin/Tazobactam Dosing Regimens in Hospitalized Patients. *Antimicrob Agents Chemother*. 2010 Jan;54(1):460-5. Epub 2009 Oct 26.

Patel N, Lubanski P, Ferro S, Bonafede M, Harrington S, Evans A, Stellrecht K, Lodise TP. Correlation Between Vancomycin MIC Values and the MIC Values of Other Gram-positive Agents Among Patients with MRSA Bloodstream Infections. *Antimicrob Agents and Chemother*. 2009 Dec;53(12):5141-4. Epub 2009 Oct 5.

Lodise TP, **Patel N**, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. *Clin Infect Dis*. 2009 Aug 15;49(4):507-14.

Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, **Patel N**. The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic Shock. *Am J Ther*. 2009 Nov-Dec;16(6):508-11.

Patel GW, **Patel N**, Lat A, Trombley KC, Enbawe S, Smith R, Lodise TP. Outcomes of Extended Infusion Piperacillin/Tazobactam for Documented Gram-negative Infections. *Diag Microbio Infect Dis*. 64 (2009) 236–240.

Patel N, McNutt LA, Lodise TP. Predictors of piperacillin-resistant *Pseudomonas aeruginosa* among patients with respiratory tract infections: the predictive value of varying exposure definitions and the risk of multiple prior antibiotic exposures. *Antimicrobial Agents and Chemotherapy*. 2008 Aug;52(8):2933-6.

Lodise TP, **Patel N**, Graves J, Kwa A, Furuno JP, Graffunder E, Lomaestro BM, McGregor JC. Predictors of 30-Day Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: The Impact of Delayed Appropriate Antibiotic Selection. *Antimicrobial Agents and Chemotherapy*. 2007 Oct;51(10):3510-5. Epub 2007 Jul 23.

Lodise TP, Miller CD, **Patel N**, Graves J, McNutt LA. Identification of Patients with Pseudomonas aeruginosa Respiratory Tract Infections at Greatest Risk for Carbapenem Resistance. *Infection Control and Hospital Epidemiology*. 2007 Aug;28(8):959-65. Epub 2007 Jun 22.

Patel N, Murdico AT. Reimbursement for Clinical Services. *Am J Health Syst Pharm*. 2007 May 1 ; 64 (9) : 926.

Published Original Research (in progress)

*Denotes work completed as a faculty member

*Cheplowitz H, **Patel N**, Kim A, Logan C, Law N, Koura D, Haste N, Medley K, Trinh J, Sanders T, Saunders I. Vaccine Response after Pneumococcal Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Under review at *J Oncol Pharm Pract*.

*Guan T, Laguna A, Soares A, Legasto CS, Block S, Saunders IM, Alvarez K, Pon T, Patel N, Mahajan A, Lee A. Evaluation of Direct Oral Anticoagulants versus Low Molecular Weight Heparins for Venous Thromboembolism Treatment in Patients with Gastrointestinal Malignancies. Under review at *Journal of Thrombosis and Thrombolysis*.

Review Articles

*Denotes work completed as a faculty member

Patel N, Bouchard J, Oliver MB, Badowski ME, Carreno JJ; Society of Infectious Diseases Pharmacists. Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*. 2021 Oct;41(10):837-850. doi: 10.1002/phar.2622. PMID: 34689348.

*Bidell MR, McLaughlin M, Faragon J, Morse C, **Patel N**. Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need. *Infect Dis Ther*. 2016 Jul 6. [Epub ahead of print]

***Patel N**, Miller CD. New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. *HIV AIDS (Auckl)*. 2012;4:61-71. doi: 10.2147/HIV.S25149. Epub 2012 Apr 27

*Miller CD, Crain J, Tran B, **Patel N**. Rilpivirine: A new addition to the anti-HIV-1 armamentarium. *Drugs Today (Barc)*. 2011 Jan;47(1):5-15.

Patel N, Scheetz M, Drusano GL, Lodise TP. Determination of Antibiotic Dosage Adjustments in Patients with Renal Impairment: Elements for Success. *J Antimicrob Chemother*. 2010 Nov;65(11):2285-90. Epub 2010 Aug 24.

Adams J, **Patel N**, Mankaryous N, Tadros M, Miller CD. Next Generation Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance and the Role of Second Generation Agents. *Ann Pharmacother*. 2010 Jan;44(1):157-65. Epub 2009 Dec 8.

Lodise TP, **Patel N**, Renaud-Mutart A, Gorodecky E. The Pharmacokinetic and Pharmacodynamic Profile of Ceftobiprole. *Diagn Microbiol Infect Dis* 2008 May;61(1):96-102. Epub 2008 Apr 2. Review

Book Chapters

*Denotes work completed as a faculty member

*Faragon J.J., **Patel N**. (2019) Cardiovascular and HIV Drug Interactions. In: Myerson M., Glesby M. (eds) Cardiovascular Care in Patients With HIV. Springer, Cham

Published Abstracts

*Denotes work completed as a faculty member

***Patel N**, Dwyer JP, Berne L, Young CL, Callahan M, Robinson AG, Lodise TP. Outcomes and Costs of Central Venous Catheter-Related *S. aureus* Bloodstream Infections in Hemodialysis Patients with SA Nares Colonization and Diabetes Mellitus. Abstract SA-PO453. Poster presentation at Kidney Week 2022. Orlando, FL. November 2022. Presenter: Patel.

***Patel N**, Blumenthal J, Burke LB, Chow K, Pacheco D, Stanczyk F, Morris S. Differences in Hormonal Measures Among Transgender Individuals Assigned Male at Birth Switching from Tenofovir Disoproxil Fumarate/Emtricitabine to Tenofovir Alafenamide/Emtricitabine for Pre-Exposure Prophylaxis. Abstract

2080. Poster presentation at IDweek2022™. Washington, DC. October 2022.
Presenter: Patel.

Huang W, Hernandez I, Tang S, Gabriel N, Sharareh N, **Patel N**, Berenbrok L, Guo J. Disparities in the association between proximity to community healthcare facilities and COVID-19 related mortality across US counties in the COVID-19-vaccine era. AcademyHealth Annual Research Meeting 2022. Washington D.C. June 2022.

Huang W, Hernandez I, Tang S, Gabriel N, Sharareh N, **Patel N**, Berenbrok L, Guo J. Rural-Urban Disparities in COVID-19 related mortality across US counties by racial and ethnic composition. AcademyHealth Annual Research Meeting 2022. Washington D.C. June 2022.

*Berenbrok LA, Tang S, Gabriel N, Guo J, Sharareh N, **Patel N**, Dickson S, Hernandez I. Access to community pharmacies: A nation-wide geographic information systems analysis. American Pharmacists Association Annual Meeting and Exposition. San Antonio, TX. March 2022.

*Lodise TP, Berne L, Young C, Callahan M, **Patel N**. Outcomes and Costs Associated with Central Venous Catheter-Related S. Aureus Bloodstream Infections in Adult Hemodialysis Patients with S. Aureus Nares Colonization. Abstract EE394. Poster presentation at The Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Meeting. Washington, DC. May 2022. Presenter: Patel/Lodise.

*Veve MP, Mercurio NJ, Sangiovanni RJ, **Patel N**. Prevalence and Predictors of P. aeruginosa among Hospitalized Patients with Diabetic Foot Infections: a Multicenter Evaluation. Abstract 00088. Poster presentation at the 31st European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria (Virtual). July 2021. Presenter: Veve.

*Hirata H, Bui A, Quach A, Trinh J, **Patel N**, Saunders IM. Real-World Usage and Clinical Outcomes Associated with Letemovir in Allogeneic HCT Patients at High Risk for CMV Reactivation. Abstract SP-115. Poster presentation at 2020 ASHP Midyear Clinical Meeting and Exhibition. Virtual Meeting. December 2020. Presenter: Hirata.

*Trinh J, Quach A, Bui A, Hirata H, Saunders IM, **Patel N**. Medication Regimen Complexity Index Over Time in Allogeneic Hematopoietic Cell Transplantation Patients Receiving Letemovir Prophylaxis or Pre-emptive Therapy. Abstract SP-

99. Poster presentation at 2020 ASHP Midyear Clinical Meeting and Exhibition. Virtual Meeting. December 2020. Presenter: Quach.

*O'Donnell JN, DeMari S, **Patel N**. Optimal Treatment of Candidemia: A Meta-Analysis Comparing Outcomes between Echinocandins and Azole Antifungals. Abstract 14200. Poster presentation at American Society of Microbiology – Microbe. Virtual Meeting. June 2020. Presenter: O'Donnell

*Cai J, Harris C, Kim S, Badowski M, Chan J, Chiampas T, Martin MT, Schriever C, **Patel N**, Michienzi S. Linkage and retention in HIV care before and after receipt of direct acting antiviral HCV treatment among patients coinfecting with HIV and HCV. Abstract Sat-67. Poster presentation at American College of Clinical Pharmacy Annual Meeting. New York City, NY. October 2019. Presenter: Cai

*Michienzi SM, Cai J, Harris C, Kim S, **Patel N**, Badowski M, Chan J, Martin MT, Schriever CA. HIV-HCV Coinfection: An investigation of CD4 T-cell reconstitution after HCV direct acting antiviral treatment. Abstract 365. Poster presentation at IDweek2019™. Washington, DC. October 2019. Presenter: Michienzi.

*Veve MP, **Patel N**, Shorman MA. Real world utilization of dalbavancin at an academic medical center. Abstract P1909. Poster presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, NL. April 2019. Presenter: Veve.

***Patel N**, Belfiore G, Hagerty M, Ackerman C, Clark J, Lowry C, Lodise T. Comparison of Incidence of Adverse Tendon Events between Fluoroquinolone or Ceftriaxone/Azithromycin Recipients among Hospitalized Community Acquired Pneumonia Patients from 2011 – 2016. Abstract P0466. Poster presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, NL. April 2019. Presenter: **Patel**.

*O'Donnell JN, Gorseth A, Belfiore G, Sangiovanni R, Yager J, Lowry C, **Patel N**. Rechallenging patients with vancomycin after previously experiencing acute kidney injury and alterations in vancomycin exposure-toxicity threshold. Abstract P2015. Poster presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, NL. April 2019. Presenter: **Patel**.

***Patel N**, Gorseth A, Amin R, Stornelli N, Pelski B, Lodise T. Comparison of Incidence of Aortic Aneurysm/Dissection between Hospitalized Community

Acquired Pneumonia Patients Receiving Either Fluoroquinolone or Ceftriaxone/Azithromycin Therapy. Abstract P0467. Poster presentation at the 29th European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, NL. April 2019. Presenter: **Patel**.

*Stornelli N, Morgansen D, Lowry C, Lodise TP, **Patel N**. Comparison of Clinical Outcomes of Oral Vancomycin Capsules and Reconstituted Intravenous Solution for Oral Use among Veterans' Affairs Patients with *Clostridium difficile* Infections. Abstract 8-231. Poster presentation at 2018 ASHP Midyear Clinical Meeting and Exhibition. Anaheim, CA. December 2018. Presenter: Stornelli.

***Patel N**, Clark J, Stornelli N, Belfiore G, Lodise TP. Comparative Evaluation of Adverse Tendon Events between Recipients of Fluoroquinolones and Ceftriaxone/Azithromycin among Veterans Affairs Patients with Community Acquired Pneumonia. Abstract 1463. Poster Presentation at IDWeek2018™. San Francisco, CA. October 2018. Presenter: **Patel**.

*Morgansen D, Stornelli N, Shah V, Lowry C, **Patel N**, Lodise TP. Comparative Effectiveness of Early-Targeted Use of Fidaxomicin versus Oral Vancomycin among Hospitalized Veterans' Affairs Patients with Infections due to *Clostridium difficile*. Abstract 4782. Poster presentation at American Society of Microbiology Microbe Meeting. Atlanta, GA. June 2018. Presenter: **Patel**.

*Sangiovanni R, Stornelli N, Amin R, Huang D, Lodise T, **Patel N**. Frequency of Vancomycin-Associated Acute Kidney Injury (V-A AKI) and Healthcare Utilization among Veterans' Affairs Patients with Skin and Skin Structure Infections. Abstract 1287. ePoster presentation at the 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, ES. April 2018. Presenter: **Patel**.

***Patel N**, Huang DB, Lodise T. Potential Cost Savings Opportunities with Targeted Use of Iclaprim (ICL) Compared to Vancomycin (VAN) among Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections Due to Potential Avoidance of VAN-Associated Acute Kidney Injury. Abstract 1290. Poster presentation at the 28th European Congress of Clinical Microbiology and Infectious Diseases. Madrid, ES. April 2018. Presenter: **Patel**.

*Sangiovanni R, Stornelli N, Yager JL, Lodise TP, Cardone KE, **Patel N**. Incidence and predictors of subsequent vancomycin-associated acute kidney injury (V-AKI) in Veterans' Affairs patients who have previously experienced V-AKI. Abstract

11. Poster presentation at National Kidney Foundation Spring Clinical Meeting. Austin, TX. April 2018. Presenter: Sangiovanni.

*Lodise TP, **Patel N**, Sweeney K, Eckburg PB. Effectiveness and Safety of Intravenous Fosfomycin at Doses of 12-24 g/day in Adult Patients: a Review of the Literature. Abstract 7-087. Poster presentation at the 52st ASHP Midyear Clinical Meeting and Exhibition. Orlando, FL. December 2017. Presenter: **Patel**.

*Najafipour K, **Patel N**, Cottrell J. Determining the Effect of GLP-1 Agonists on Total Daily Insulin Dose in Veterans Receiving a Basal-Bolus Insulin Regimen. Abstract 1-270. Poster presentation at the 52st ASHP Midyear Clinical Meeting and Exhibition. Orlando, FL. December 2017. Presenter: Najafipour.

***Patel N**, Clark J, Murray J, Bowles J, Lodise TP. Incidence and Predictors of Fluoroquinolone-Associated Adverse Tendon Events among Veterans Affairs Patients with Community Acquired Bacterial Pneumonia. Abstract 66887. Poster presentation at IDWeek 2017™. San Diego, CA. October 2017. Presenter: **Patel**.

*Britt NS, **Patel N**, Potter EM, Steed ME. Changing Epidemiology of Carbapenem-Resistant Enterobacteriaceae Bloodstream Infections in United States Veterans Affairs Hospitals, 2004-2014. Abstract 63317. Poster presentation at IDWeek 2017™. San Diego, CA. October 2017. Presenter: Britt.

*Britt NS, **Patel N**, Potter EM, Steed ME. Polymyxin Monotherapy versus Combination Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection: A National Cohort Study. Abstract 63375. Poster presentation at IDWeek 2017™. San Diego, CA. October 2017. Presenter: Britt.

*Britt NS, Steed ME, Potter EM, **Patel N**. Clinical Outcomes of Methicillin-Resistant *Staphylococcus aureus* Bacteremia Treated with Ceftaroline Fosamil. Abstract SUN-281. Poster presentation at American Society of Microbiology Microbe Meeting. New Orleans, LA. June 2017. Presenter: Britt.

***Patel N**, Lo A, Barriere S, Lodise T. Quantitative Evaluation Of Telavancin Exposure-Response Relationships Among Patients In The Assessment Of Telavancin For Treatment Of Hospital-Acquired Pneumonia (ATTAIN) Trials. Late breaker abstract LB2. Poster presentation at American Society of Microbiology Microbe Meeting. New Orleans, LA. June 2017. Presenter: **Patel**.

*Sangiovanni RJ, Yager J, Carreno JJ, O'Donnell JN, Lowry C, Carlyn C, **Patel N**. Retreatment with Vancomycin and Subsequent Risk of Acute Kidney Injury (AKI) among Veterans' Affairs Patients who have Previously Experienced Vancomycin-

associated AKI. Abstract SAT-180. Poster presentation at American Society of Microbiology Microbe Meeting. New Orleans, LA. June 2017. Presenter: **Patel**.

*O'Donnell JN, Bidell MR, **Patel N**. Optimal treatment of MSSA blood stream infections: A meta-analysis of cefazolin versus antistaphylococcal penicillins. Abstract FRI-215. Poster presentation at American Society of Microbiology Microbe Meeting. New Orleans, LA. June 2017. Presenter: O'Donnell.

*Sangiovanni RJ, Yager J, Donadio A, Farrow G, **Patel N**. Use of vancomycin in VISN-2 patients who have previously experienced vancomycin-associated acute kidney injury (AKI): Predictors and outcomes of secondary vancomycin-associated AKI. Abstract 225960. Poster presentation at the 51st ASHP Midyear Clinical Meeting and Exhibition. Las Vegas, NV. December 2016. Presenter: Sangiovanni

*Yager J, Faragon J, **Patel N**. Quantifying the minimum adherence threshold associated with the development of reverse transcriptase mutations among HIV-infected Veterans' Affairs patients receiving antiretroviral therapy. Abstract 225954. Poster Presentation at the 2016 ASHP Midyear Clinical Meeting. Las Vegas, NV. December 2016. Presenter: Yager.

*Ahmed AA, Schriever C, Amin R, Delehanty KR, Yager J, **Patel N**. Comparing the Population-Based Frequency of Contraindicated Drug-Drug Interactions between Daclatasvir/Sofosbuvir (DAC/SOF), Grazoprevir/Elbasvir (GZR/EBV), Ledipasvir/Sofosbuvir (LDV/SOF), Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin (OMB/PTV/RTV + DSV ± RBV) and Simeprevir/Sofosbuvir (SIM/SOF) for Treatment of Hepatitis C Monoinfection. Abstract 60260. Poster presentation at IDWeek 2016™. New Orleans, LA. October 2016. Presenter: **Patel**.

*Britt NS, Potter EM, **Patel N**, Steed ME. Clinical Outcomes In Vancomycin-Resistant *Enterococcus* (VRE)/Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bloodstream Coinfection Treated With Daptomycin Or Linezolid. Abstract 396. Poster presentation at American Society for Microbiology Microbe Meeting. Boston, MA. June 2016. Presenter: Britt.

*Britt NS, Potter EM, **Patel N**, Steed ME. Derivation And Validation Of A Mortality Risk Assessment Model For Vancomycin-Resistant Enterococcal (Vre) Bacteremia Based On Source Of Infection. Session 333. Platform presentation at American Society for Microbiology Microbe Meeting. Boston, MA. June 2016. Presenter: Britt.

*Schriever C, Ahmed A, Delehanty KR, Yager J, Farrow G, Kashtan R, Lodise T, **Patel N**. Comparison of frequencies of drug-drug interactions between sofosbuvir/ledipasvir and ombitasvir/dasabuvir/paritaprevir/ritonavir +/- ribavirin

among HIV/HCV coinfecting patients. Abstract SAT-223. Poster presentation at the European Association for the Study of the Liver – International Liver Congress. Barcelona, ES. April 2016. Presenter: **Patel**

*Yager J, Lodise T, **Patel N**. Minimum adherence threshold necessary to achieve virologic suppression. Abstract 1995. Poster presentation at the 26th European Congress on Clinical Microbiology and Infectious Diseases. Amsterdam, NL. April 2016. Presenter: **Patel**

***Patel N**, Yager J, McGuey L, Hoye-Simek A, Lodise T. Relationship between single-tablet regimen and adherence to HIV and non-HIV medications. Abstract 1998. Poster presentation at the 26th European Congress on Clinical Microbiology and Infectious Diseases. Amsterdam, NL. April 2016. Presenter: **Patel**

***Patel N**, Hecox Z, Morse C, Sullivan S, Hoye-Simek A, Yager J, Lodise T. Maintenance of non-HIV cardiometabolic comorbidity control among HIV-infected veterans' affairs patients: a comparison between single tablet and multiple tablet antiretroviral regimens. Abstract 1991. Poster presentation at the 26th European Congress on Clinical Microbiology and Infectious Diseases. Amsterdam, NL. April 2016. Presenter: **Patel**

*Yager J, Lodise T, **Patel N**. Minimum adherence threshold needed for maintenance of virologic suppression. Abstract 1993. Platform presentation at the 26th European Congress on Clinical Microbiology and Infectious Diseases. Amsterdam, NL. April 2016. Presenter: Yager

*Britt NS, Potter EM, **Patel N**, Steed ME. Association between time to treatment and clinical outcomes in vancomycin-resistant enterococcal bloodstream infection. Abstract 2570. Platform Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA. September 2015. Presenter: Britt.

*Jakeman B, Nasiri M, Ruth L, Morse C, Mahatme S, **Patel N**. Abstract H780. Poster Presentation at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; September 2015. Presenter: **Patel**

*Britt NS, Potter EM, **Patel N**, Steed ME. Comparative effectiveness of daptomycin versus linezolid in vancomycin-resistant enterococcal bloodstream infection: a national, propensity score matched cohort study. Abstract 3-114. Poster Presentation at the 49th American Society of Health-Systems Pharmacists Midyear Clinical Meeting and Exposition. Anaheim, CA. December 2014. Presenter: Britt

*Britt NS, **Patel N**, Horvat RT, Steed ME. Vancomycin Area Under the Curve (AUC)/Minimum Bactericidal Concentration (MBC) Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia. Abstract A-1314. Poster Presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. September 2014. Presenter: Britt.

*Britt NS, Potter EM, **Patel N**, Steed ME. Linezolid versus Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infections. Abstract L-401. Poster Presentation at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. September 2014. Presenter: Britt.

*Veve M, Bottiglieri SM, Bliss S, Larche N, **Patel N**. Death within same year of diagnosis of hepatocellular carcinoma: incidence and predictors of early mortality among Veterans' Affairs patients. Abstract 1-435. Poster Presentation at 2013 American Society of Health-Systems Pharmacists Midyear Clinical Meeting & Exhibition. Orlando FL. December 2013. Presenter: Veve

***Patel N**, Nasiri M, Kwon S, Miller C, Tseng A, Miller CD, Fish D. Association between Use of Erectile Dysfunction Drugs and Syphilis among HIV-infected Men. Abstract #827. Poster Presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Denver, CO. September 2013. Presenter: **Patel**.

*Chen CN, **Patel N**, Tseng A, Lalonde RG, Thibeault D, Sheehan NL. Darunavir therapeutic drug monitoring in treatment-experienced HIV infected patients receiving highly potent antiretroviral regimens: results from the PRIDE study. Abstract #P-22. 14th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, Netherlands. April 2013. Presenter: **Sheehan**

***Patel N**, Nasiri M, Kwon S, Miller C, McNutt LA, Fish D. Association between Phosphodiesterase Type 5 Inhibitor and Sexually Transmitted Infections among HIV-infected Men. Abstract #X-196. Poster Presentation at the 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, VA. March 2013. Presenter: **Patel**

*Fitzpatrick B, Bottiglieri SM, Larche N, **Patel N**. Clinical Predictors of Mortality among Veterans Affairs Patients with Hepatocellular Carcinoma. Abstract #4-312. Poster Presentation at the 2012 American Society of Health-Systems Pharmacists Midyear Clinical Meeting & Exhibition. Las Vegas, NV. December 2012. Presenter: Fitzpatrick

*Lodise TP, **Patel N**, Rivera A, Tristani L, VanDeWal H, Smith R, McNutt LA. A Comparative Evaluation of Serotonin Toxicity among Veterans' Affairs Patients

Receiving Linezolid and Vancomycin. Abstract #1318. Platform Presentation at IDweek™ 2012. San Diego, CA. October 2012. Presenter: Lodise

*Assimon MM, Bruni E, McNutt LA, Mason DL, **Patel N**. Incidence and predictors of hepatitis B vaccine non-response among hemodialysis patients. Abstract # 145. Poster Presentation at the American College of Clinical Pharmacy Annual Meeting 2012. Hollywood, FL. October 2012. Presenter: Assimon

*Casapao AM, Leonard SN, Davis SL, Lodise TP, **Patel N**, Goff DA, LaPlante KL, Potoski BA, Rybak MJ. Clinical outcomes in patients with heterogeneous vancomycin-intermediate *Staphylococcus aureus*. Abstract #2430. Platform Presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 2012 Presenter: Casapao.

*Butterfield JM, **Patel N**, Mueller BA, Grabe D, Cardone KE, Salama NN, Lodise TP. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of hemodialysis patients. Abstract #903. Poster Presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. September 2012 Presenter: Butterfield.

***Patel N**, Bruni E, Tizzano V, Mason D, Miller C. Association between Vitamin D and viral load (HIVRNA) among HIV-infected patients. Abstract #P-2125. Poster Presentation at the 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, England. April 2012. Presenter: **Patel**.

***Patel N**, Veve M, Tizzano V, Sheth N, Miller C. Quantifying the incidence and magnitude of liver injury among HIV-infected patients receiving raltegravir-containing antiretroviral therapy. Abstract #P-2133. Poster Presentation at the 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, England. April 2012. Presenter: **Patel**.

***Patel N**, Veve M, Miller C. Prevalence of QTc prolongation among HIV-infected patients: a clinical prediction tool to determine high-risk patients. Abstract #R-2734. Published Abstract at the 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, England. April 2012. Presenter: **Patel**.

***Patel N**, Tizzano V, Bruni E, Veve M, Miller C. Quantifying the incidence and severity of acute renal failure among HIV-infected adults receiving tenofovir-based antiretroviral therapy. Abstract #R-2735. Published Abstract at the 22nd European Congress of Clinical Microbiology and Infectious Diseases. London, England. April 2012. Presenter: **Patel**.

*Fiorenza M, **Patel N**, Dihmess A, Woo B, Lodise TP. Predictors of Infections Caused by Carbapenem-Resistant Enterobacteriaceae (CRE) Possessing the *bla_{KPC}* gene Among Hospitalized Patients. Abstract #4-174. Poster Presentation at the 45th American Society of Health-Systems Pharmacists Mid-Year Clinical Meeting. Anaheim, CA. December 2010. Presenter: Fiorenza.

***Patel N**, Fiorenza M, Dihmess A, Martis P, Graffunder E, Harrington SM, Lodise T. Predictors of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections Among Patients with Enterobacteriaceae Infections. Abstract #227. Poster Presentation at the 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, BC. October 2010. Presenter: Lodise

Cardone KE, Lodise TP, **Patel N**, Manley HJ, Hoy CD, Meola SA, Drusano GL, Grabe DW. Use of population pharmacokinetic modeling and Monte Carlo simulation to determine optimal daptomycin dosing in patients on continuous ambulatory peritoneal dialysis. American Society of Nephrology Renal Week 2010. Denver, CO. October 2010. Presenter: Grabe

***Patel N**, Veve M, Abdelsayed S, Miller CD. Clinical/Virologic Outcomes among HIV-Infected Patients (Pts) Receiving Dose-Adjusted (DA) Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Abstract #H-208. Poster Presentation at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, MA. September 2010. Presenter: **Patel**

*Miller CD, Abdelsayed S, Veve M, **Patel N**. Predictors of Clinically Significant Antiretroviral (ARV) Drug Interactions among First-Line ARV Regimens. Abstract #H-210. Poster Presentation at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, MA. September 2010. Presenter: **Miller**

Tristani L, **Patel N**, Woo B, Dihmess A, VanDeWall H, Li H, Smith R, Lodise T. Lack of serotonin syndrome among Veteran Affairs patients receiving linezolid. Abstract # 464. Poster Presentation at the 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria. April 2010. Presenter: **Patel**

Lodise T, **Patel N**, Hedge S, Shaw J, Barriere S, Drusano, GL. Mouse thigh MRSA infection model data and mathematical modelling to determine telavancin dosing for complicated skin and skin structure infection trials. Abstract # 469. Poster Presentation at the 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria. April 2010. Presenter: Lodise

Lodise T, **Patel N**, Hedge S, Shaw J, Barriere S. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections

with varying degrees of renal function. Abstract #468. Oral Presentation at the 20th European Congress of Clinical Microbiology and Infectious Diseases. Vienna, Austria. April 2010. Presenter: Lodise

Fiorenza MA, **Patel N**, Dihmess A, Martis P, Lodise TP. Clinical Characteristics and Outcomes of Patients with Carbapenem-Resistant Enterobacteriaceae (CRE). Abstract #2-146. Poster Presentation at the 44th Midyear Clinical Meeting and Exhibition, Las Vegas, NV. December 2009. Presenter: Fiorenza

Hart RB, **Patel N**, Gray CM, Feelymeyer J, Wymer S, Lodise TP, McNutt LA. Relationship between municipal water fluoridation and preterm birth in Upstate New York Rachel. Poster presentation at 137th American Public Health Association Annual Meeting. Philadelphia, PA. November 2009. Abstract # 197468. Presenter: Hart

Patel N, Pallotta K, Grabe DW, Meola S, Hoy C, Drusano GL, Lodise TP. Daptomycin (D) Concentration (Conc) Time Profile in Hemodialysis (HD) Patients (Pts). Abstract #1242. Platform Presentation at the 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA. October 2009. Presenter: **Patel**

VanDeWal H, **Patel N**, Tristani L, Grifasi M, Dihmess A, Smith R, Lodise TP. Incidence of Thrombocytopenia (TCP) Among Veterans' Affairs (VA) Patients (Pts) that Received Linezolid (L). Abstract #200. Poster Presentation at the 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA. October 2009. Presenter: VanDeWal

Patel N, Grifasi, M, Pai M, Rodvold K, Drusano GL, Lodise TP. Vancomycin (V): We Can Not Get There From Here. Abstract #193. Poster Presentation at the 47th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA. October 2009. Presenter: Lodise

Patel N, Pallotta K, Grabe DW, Meola S, Hoy C, Drusano GL, Lodise TP. Daptomycin (D) Pharmacokinetics (PK) in Patients (Pts) Receiving Standardized 3X Weekly Hemodialysis (HD). Abstract #A1-1274. Poster Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA. September 2009. Presenter: **Patel**

Scheetz MH, **Patel N**, Drusano GL, Lodise TP. Examination of the Current Renal Dose Adjustment for Piperacillin/Tazobactam (PT). Poster Presentation at 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC. October 2008. A1906. Presenter: Scheetz

Patel GW, **Patel N**, Lat A, Lodise TP. Outcomes of Extended Infusion Piperacillin-Tazobactam for Documented Gram-Negative Infections. Poster Presentation at 48th

Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC. October 2008. K3514.
Presenter: **Patel N**

Patel N, Graffunder E, Evans A, Helmecke M, Stellrecht K, Lodise TP. Predictors of hVISA among patients with MRSA bacteraemia. Poster Presentation at 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain. April 2008. P1462. Presenter: **Patel**

Patel N, Graffunder E, Evans A, Helmecke M, Stellrecht K, Lodise TP. Relationship between MRSA strains expressing hVISA and outcomes among patients with MRSA bloodstream infections treated with vancomycin. Poster Presentation at 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain. April 2008. P1461. Presenter: **Patel**

Patel N, Lodise TP. Predictors of piperacillin-resistant *Pseudomonas aeruginosa* among patients with respiratory tract infections: the predictive value of varying exposure definitions and the risk of multiple prior antibiotic exposures. Poster Presentation at 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain. April 2008. P1268. Presenter: **Patel**

Patel N, Lee H, Loutfy M, Raboud J, Diong C, Yoong D, Rachlis A, et al. Immunologic and virologic effectiveness of tipranavir/ritonavir (TPV/r)-based regimens in treatment-experienced patients in clinical practice. Poster Presentation at Canadian Association of HIV Research 16th Annual Meeting, Toronto, ON. April 2007.
Presenter: **Patel**

Patel N, Tseng A, Walmsley S, Lalonde R, Sheehan NL, Loutfy M. Evaluating the Pharmacokinetic Profile of Darunavir ethanolate/ritonavir to Determine the Most Appropriate Predictor of Virologic Response in Advanced HIV-1 Infected Patients – A prospective, multi-center, open-label, observational analysis – Poster presentation at the 41st ASHP Midyear Clinical Meeting, Anaheim, CA. December 2006. Presenter: **Patel**

Lodise TP, **Patel N**, Graves J, Lomaestro BM. Relationship between Prior Antibiotic Exposure and Multi-Drug Resistant *Pseudomonas aeruginosa*. Poster presentation at 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France. April 2006. Presenter: Lodise

Patel N, Lodise TP. Risk factors for Carbapenem-Resistant Among Patients with *Pseudomonas aeruginosa* Respiratory Tract Infections. Poster Presentation at 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice, France. April 2006. Presenter: Lodise

Patel N, Lodise TP. Risk Factors for Carbapenem-Resistant *Pseudomonas aeruginosa* Respiratory Tract Infections. Poster presentation at the 40th ASHP MCM, Las Vegas, NV. December 2005. Presenter: **Patel**

Lodise TP, Schwarzbard L, **Patel N**, Gupta R, Esker S. Comparison of Glucose Intolerance between Gatifloxacin and Piperacillin-Tazobactam in Elderly, Hospitalized Patients. Platform Presentation at 2004 WVU Research Conference, Morgantown, WV. October 2004. Presenter: **Patel**

Lodise TP, **Patel N**, Graves JR, Gupta R. Impact of Delayed Treatment *Pseudomonas Aeruginosa* Bacteremia. Poster Presentation at 2004 WVU Research Conference, Morgantown, WV. October 2004. Presenter: Graves

Invited Presentations

Maximizing ExamSoft Features

Development seminar for faculty at Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego. La Jolla, CA. March 2021.

Faculty Forum – The Nomadic Research Program

Faculty presentation on new and existing research projects at Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California San Diego. La Jolla, CA. November 2020.

New Investigator Spotlight – Drug Exposure Studies in Transgender PrEP Patients

New faculty spotlight of new studies evaluating drug exposure in transgender PrEP recipients. HIV rounds at the Antiviral Research Center at University of California San Diego. La Jolla, CA. November 2019.

Annual Hepatitis C Update

Continuing education presentation to pharmacists and students at the American Pharmacists Association Annual Meeting. Seattle, WA. March 2019.

Treatment for Hepatitis C: New Tests, New Drugs & New Recommendations.

Continuing education presentation to American Nurses Association of New York. Albany, NY. September 2017.

Drug Interactions Involving Medications for HIV, HCV and Mental Health Conditions. ACPE accredited continuing education telemedicine series broadcast to all New York State Department of Corrections pharmacists; Albany Medical Center HIV Clinic, Albany, NY. January 2017.

Medication Errors in HIV. ACPE accredited continuing education; Albany College of Pharmacy & Health Sciences, Albany, NY. January 2017.

Medication Errors in HIV. ACPE accredited continuing education program for the Onondaga Pharmacists Society; Syracuse, NY. October 2016.

Medication Errors in HIV. ACPE accredited continuing education program for the Capital Area Pharmacists Society; Albany, NY. September 2016.

Updates in Epidemiology and Treatment of Sexually Transmitted Infections. ACPE accredited continuing education; Albany College of Pharmacy & Health Sciences, Albany, NY. September 2016.

Medication Errors in HIV. ACPE accredited continuing education program at the Pharmacists' Society of the State of New York Annual Meeting; Rye Brook, NY. June 2016.

Medication Errors in HIV. ACPE accredited continuing education telemedicine series broadcast to all New York State Department of Corrections pharmacists; Albany Medical Center HIV Clinic, Albany, NY. June 2016.

Updates in Epidemiology and Treatment of Hepatitis C Infection. ACPE accredited continuing education; Albany College of Pharmacy & Health Sciences, Albany, NY. February 2016.

Updates in Epidemiology and Treatment of HIV. ACPE accredited continuing education; Albany College of Pharmacy & Health Sciences, Albany, NY. February 2016.

HIV Update – 2015. ACPE accredited continuing education web-based broadcast to Upstate New York Veterans' Healthcare Administration (VISN-2) pharmacists; Stratton Veterans' Affairs Medical Center, Albany, NY. October 2015.

Management of HIV Infection: 2015 Update. Grand rounds to house staff at Samuel S. Stratton Veterans' Affairs Medical Center. Albany, NY. June 2015.

Overview of Sexually Transmitted Infections for Providers. ACPE accredited continuing education telemedicine series broadcast to all New York State Department of Corrections pharmacists; Albany Medical Center HIV Clinic, Albany, NY. May 2015.

What's New in HCV Pharmacotherapy: A case-based approach. ACPE accredited continuing education to regional pharmacists; American Health Resources, Albany, NY. April 2015.

HCV Update – 2015. ACPE accredited continuing education web-based broadcast to Upstate New York Veterans' Healthcare Administration (VISN-2) pharmacists; Stratton Veterans' Affairs Medical Center, Albany, NY. April 2015.

HIV Resistance Overview for Providers – 2015. ACPE accredited continuing education telemedicine series broadcast to all New York State Department of Corrections pharmacists; Albany Medical Center HIV Clinic, Albany, NY. February 2015.

HCV Update 2015. Grand rounds to physicians at Nathan Littauer Hospital. Gloversville, NY. February 2015.

What's New in HCV Pharmacotherapy. ACPE accredited continuing education; Albany College of Pharmacy & Health Sciences, Albany, NY. February 2015.

Psychotropic Medications – Interactions with HIV and HCV Medications. ACPE accredited continuing education telemedicine series broadcast to all New York State Department of Corrections pharmacists; Albany Medical Center HIV Clinic, Albany, NY. December 2014.

Back to Basics: A Primer on the Care and Management of Patients with Hepatitis C Infection. ACPE accredited continuing education; Albany College of Pharmacy & Health Sciences, Albany, NY. January 2014.

Medication errors: A focus on the HIV-infected patient. ACPE accredited continuing education telemedicine series broadcast to all New York State

Department of Corrections pharmacists; Albany Medical Center HIV Clinic, Albany, NY. June 2013.

Sexually Transmitted Infections: An Update. ACPE accredited continuing education; Albany College of Pharmacy & Health Sciences, Albany, NY. March 2013.

HIV and Hepatitis C Pharmacotherapy: An American Approach. Grand rounds presented to infectious diseases clinicians in the city of Almaty and Almaty AIDS Center. Almaty, Kazakhstan. February 2013

Application of Research Study Designs to Implementing and Developing a Sustainable Research Agenda. Invited lecture presented to clinical research faculty at Kazakh National Medical University – School of Medicine. Almaty, Kazakhstan. February 2013

Hepatitis B Pharmacotherapy and Clinical Considerations for Patients with HIV Infection. ACPE accredited continuing education telemedicine series broadcast to all New York State Department of Corrections pharmacists; Albany Medical Center HIV Clinic, Albany, NY. January 2013

Contemporary Issues surrounding Vancomycin Laboratory Monitoring. Grand rounds to laboratory physicians at University of Massachusetts Memorial Hospital. Worcester, MA. September 2012.

Career transitions: Academia, Clinical and Industry. ACPE accredited continuing education; Society of Infectious Diseases Pharmacists Annual Meeting, 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Sept. 2012.

The medication-based treatment approach for hepatitis C-infected patients. ACPE accredited continuing education; Northeast Chapter of the New York State Council of Health-Systems Pharmacists. June 2012.

Medication errors: A focus on the HIV-infected patient. ACPE accredited continuing education telemedicine series broadcast to all New York State Department of Corrections pharmacists; Albany Medical Center HIV Clinic, Albany, NY. June 2012

The medication-based treatment approach for hepatitis C-infected patients. ACPE accredited continuing education; Albany College of Pharmacy & Health Sciences, Albany, NY. February 2012.

Sexually Transmitted Infections & the Expedited Partner Therapy Legislation in NYS. ACPE accredited continuing education; Capital Area Pharmacists Society, Saratoga, NY. May 2011.

HIV Update. ACPE accredited continuing education; Capital Area Pharmacists Society, Saratoga, NY, May 2011.

HIV Update. ACPE accredited continuing education; Mohawk Valley Pharmacists' Society, Utica, NY. November 2010.

Sexually Transmitted Infections. ACPE accredited continuing education; Mohawk Valley Pharmacists' Society, Utica, NY. November 2010.

HIV Update. ACPE accredited continuing education; New York State Society of Health-Systems Pharmacists, Albany, NY. January 2010.

Inferential Statistics for the Clinician. Invited Presentation; Albany Medical Center Neonatal Department, Albany, NY. August 2009.

Inferential Statistics for the Clinician. Invited Presentation; Albany Medical Center Neonatal Department, Albany, NY. July 2009.

Sexually Transmitted Infections. ACPE accredited continuing education; Albany College of Pharmacy and Health Sciences, Albany, NY. February 2009.

What's New in HIV- Drugs and Indicators. ACPE accredited continuing education; Capital Area Pharmacists Society, Saratoga Springs, NY. May 2008

What's New in HIV- Drugs and Indicators. ACPE accredited continuing education; Albany College of Pharmacy and Health Sciences, Albany, NY. April 2008

RESEARCH GRANTS

Grants - Awarded

*Denotes work completed as a faculty member

*TITLE: RENAL EFFECTS OF HORMONES/BIOMARKERS IN TRANSGENDER PREP PATIENTS.

Funding Source: California HIV/AIDS Research Program

Amount: \$260,000

Performance dates: 2/1/2020 – 6/30/2022

Role: Principal Investigator

Co-Investigators: Sheldon Morris, M.D., Linda Awdishu, Pharm.D.

*TITLE: BIDIRECTIONAL EFFECT OF EXOGENOUS HORMONES AND F/TAF IN TRANSGENDER PATIENTS RECEIVING TAF-BASED PREP AND THE IMPACT ON VARIOUS ADHERENCE MEASURES. ISR-US-19-10881/ CO-US-412-5792

Funding Source: Gilead Sciences

Amount: \$190,708 (includes 2021 budget amendment)

Performance dates: 1/1/2020 – 6/30/2022

Role: Principal Investigator

Co-Investigators: Jill Blumenthal, M.D.

*TITLE: MODELING MICRO-ELIMINATION OF HEPATITIS C VIRUS INFECTION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS IN THE UNITED STATES VETERANS AFFAIRS HEALTHCARE SYSTEM.

Funding Source: Subaward from University of Kansas via Gilead Sciences NoCo HCV Microelimination Program

Amount: \$120,283 (subaward) of \$596,895 (full award)

Performance dates: 7/1/2019 – 6/30/2022

Role: Co-Investigator

Principal Investigator: Nicholas Britt, Pharm.D., M.S.

*TITLE: REAL-WORLD EFFECTIVENESS AND SAFETY OF FLUOROQUINOLONES VERSUS OTHER ANTIMICROBIALS AMONG ELDERLY, HOSPITALIZED VETERANS' AFFAIRS PATIENTS WITH COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

Funding Source: Society of Infectious Diseases Pharmacists

Amount: \$30,000

Performance dates: 10/1/17 – 1/31/19

Role: Principal Investigator

Co-Investigator: Thomas Lodise, Pharm.D.

*TITLE: IDENTIFICATION OF PATIENTS POPULATIONS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS AT GREATEST RISK FOR

PROLONGED HOSPITAL STAY AND HOSPITAL RE-ADMISSIONS WITH EMPIRIC TREATMENT WITH VANCOMYCIN

Funding Source: Motif, Inc.

Amount: \$34,999

Performance dates: 9/1/17 – 8/31/18

Role: Principal Investigator

Co-Investigator: Thomas Lodise, Pharm.D.

*TITLE: COMPARATIVE EFFECTIVENESS OF EARLY-TARGETED USE OF FIDAXOMICIN VERSUS ORAL VANCOMYCIN AMONG HOSPITALIZED VETERANS' AFFAIRS PATIENTS WITH INFECTIONS DUE TO CLOSTRIDIUM DIFFICILE

Funding Source: Merck & Co, Inc.

Amount: \$76,483

Performance dates: 7/1/17 – 06/30/19

Role: Co-Principal Investigator

Principal Investigator: Thomas Lodise, Pharm.D., Ph.D. & Nimish Patel, Pharm.D., Ph.D.

*TITLE: PREVALENCE OF CONTRAINDICATED DRUG-DRUG INTERACTIONS BETWEEN SOFOSBUVIR/LEDIPASVIR AND OMBITASVIR/DASABUVIR/ABT450/RITONAVIR +/- RIBAVIRIN AMONG PATIENTS MONOINFECTED WITH HEPATITIS C INFECTION

Funding Source: Gilead Sciences

Amount: \$36,371

Performance dates: 1/1/15 – 12/31/15

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

*TITLE: PREVALENCE OF CONTRAINDICATED DRUG-DRUG INTERACTIONS AMONG PATIENTS COINFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS C: COMPARISON BETWEEN SOFOSBUVIR/LEDIPASVIR AND OMBITASVIR/DASABUVIR/ABT450/RITONAVIR +/- RIBAVIRIN

Funding Source: Gilead Sciences

Amount: \$26,720

Performance dates: 12/1/14 – 11/30/15

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

*TITLE: CLINICAL OUTCOMES ASSOCIATED WITH SINGLE TABLET REGIMENS: RELATIONSHIP BETWEEN ANTIRETROVIRAL THERAPY PILL BURDEN AND CONTROL OF CONCOMITANT COMORBIDITIES AMONG HIV-INFETED PATIENTS

Funding Source: Gilead Sciences

Amount: \$54,228

Performance dates: 7/1/14 – 6/30/15

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., M.S.

*TITLE: FREQUENCY AND NATURE OF CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTIONS IN THE PRIMARY CARE SETTING: A COMPARATIVE ANALYSIS AMONG HIV-INFECTED PATIETNS USING ANTIRETROVIRAL THERAPY

Funding Source: Merck & Co., Inc.

Amount: \$53,249

Performance dates: 12/1/13 – 11/30/14

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., M.S.

*TITLE: IDENTIFYING THE PREVALENCE AND AVAILABLE MANAGEMENT STRATEGIES OF DRUG INTERACTIONS WITH TELAPREVIR IN HIV/HCV CO-INFECTED PATIENTS

Funding Source: Vertex Pharmaceuticals, Inc.

Amount: \$27,800

Performance dates: 7/15/12 – 7/14/13

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., M.S.

*TITLE: INCIDENCE OF THROMBOCYTOPENIA AND SEROTONIN SYNDROME AMONG VETERANS AFFAIRS PATIENTS: A COMPARISON BETWEEN LINEZOLID AND VANCOMYCIN USING AN INTENSIVE SEARCH ALGORITHM

Funding Source: Pfizer, Inc.

Amount: \$25,000

Performance dates: 9/01/10-6/30/11

Role: Co-Investigator

Principal Investigator: Thomas Lodise, Pharm. D.

TITLE: EVALUATING THE IMPACT OF VANCOMYCIN MIC AND VANCOMYCIN EXPOSURE PROFILE ON THE OUTCOMES OF PATIENTS WITH CA-MRSA AND HCA-MRSA BLOODSTREAM INFECTIONS (2009-0008-12)

Funding Source: Cubist Pharmaceuticals
Amount: \$150,640
Performance dates: 8/01/09-7/31/10
Role: Co-Investigator
Principal Investigator: Thomas Lodise, Pharm. D.

TITLE: MOLECULAR AND CLINICAL EPIDEMIOLOGY OF CARBAPENEM-RESISTANT

ENTEROBACTERIACEAE (35923)

Funding Source: Merck & Co, Inc.

Amount: \$30,625

Performance dates: 1/01/09-6/30/10

Role: Co-Investigator

Principal Investigator: Thomas Lodise, Pharm.D.

Co-Investigators: Eileen Graffunder, MS, KA Stellrecht Ph.D.

TITLE: ERTAPENEM PHARMACOKINETICS IN PATIENTS ON CONTINUOUS AMBULATORY PERITONEAL DIALYSIS

Funding Source: Merck & Co, Inc.

Amount: \$113,297.50

Performance dates: 2/01/09-6/30/10

Role: Co-Investigator

Principal Investigator: KE Pallotta, Pharm.D.

Co-Investigators: Darren Grabe, Pharm.D., Thomas Lodise, Pharm. D., C Hoy, MD. S Meola, RN.

TITLE: EPIDEMIOLOGY OF VANCOMYCIN SUSCEPTIBILITY PHENOTYPES ASSOCIATED WITH SUBOPTIMAL CLINICAL OUTCOMES AMONG PATIENTS MRSA BLOODSTREAM INFECTIONS IN UPSTATE NEW YORK.

Funding Source: Upstate New York Consortium for Healthcare Research and Quality and the Upstate New York Translational Research Network Pilot Research Grant (1 UL1 RR024160-01)

Amount: \$48,225.00

Performance dates: 10/01/08- 4/30/10

Role: Co-Investigator

Co-Principal Investigators: Thomas Lodise, Pharm.D., Brian Tsuji, Pharm.D.

Co-Investigators: Alan Forrest, Pharm.D., Elizabeth Dodds Ashley, Pharm. D. MHS

TITLE: DAPTOMYCIN PHARMACOKINETICS IN THRICE-WEEKLY HEMODIALYSIS PATIENTS (IIS-0020-1-06).

Funding Source: Cubist Pharmaceuticals

Amount: \$241,717.50

Performance dates: 10/01/08- 10/31/09

Role: Co-Investigator

Co-Principal Investigators: Thomas Lodise, Pharm.D., Darren Grabe, Pharm.D.

Co-Investigators: GL Drusano, MD, KE Pallotta, Pharm.D., C Hoy, MD. S Meola, RN.

Grants – Unfunded/Awaiting Decision

*Denotes work completed as a faculty member

?*Decision pending

TITLE: INTERCONNECTED RELATIONSHIP BETWEEN SEX HORMONES, GUT MICROBIOTA AND MECHANISMS OF KIDNEY FUNCTION/INJURY

Funding Source: Paul G. Allen Frontiers Group

Amount: \$1,500,000

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigators: Linda Awdishu, Pharm.D., Sheldon Morris, M.D.

*?TITLE: SPATIAL ACCESS TO HEALTH CARE AS A DETERMINANT OF DIABETES MANAGEMENT AND OUTCOMES

Funding Source: National Institutes of Health

Amount: \$3,810,992

Role: Multiple Principal Investigator

Principal Investigators: Nimish Patel, Pharm.D., Ph.D., Inmaculada Hernandez, Pharm.D., Ph.D., Jingchuan Guo, M.D., Ph.D.

Co-Investigators: Lucas Berenbrok, Pharm.D., Kenneth Cusi, M.D., Nasser Sharareh, Ph.D.

*TITLE: RELATIONSHIP BETWEEN ULTRA-SENSITIVE QUANTIFICATION OF CYTOMEGALOVIRUS VIA MICROBIAL CELL-FREE DNA TESTING AND CLINICALLY-SIGNIFICANT CMV INFECTION AMONG HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS

Funding Source:

Amount: \$454,478

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigators: Ajay Bharti, M.D., Cathy Logan, M.D.

*TITLE: INCIDENCE & PREDICTORS OF LARGE WEIGHT CHANGES AMONG RECIPIENTS OF INTEGRASE INHIBITORS AND RELATIONSHIP OF WEIGHT CHANGES AND CLINICAL OUTCOMES

Funding Source: Gilead Sciences

Amount: \$410,863

Submission date: March 2022

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigators: Jeffrey Yin, Pharm.D, Maile Karris, M.D.

?TITLE: CHANGES IN WEIGHT AFTER SWITCHING OFF OF INTEGRASE STRAND TRANSFER BASED REGIMENS: DOES THE NEXT REGIMEN MATTER?

Funding Source: Janssen Pharmaceuticals, Inc.

Amount: \$324,848

Submission date: March 2022

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigators: Jeffrey Yin, Pharm.D

*TITLE: PILOT STUDY TO ASSESS PERFORMANCE OF KARIUS TEST AGAINST BONE BIOPSY AMONG PATIENTS WITH DIABETIC FOOT INFECTIONS

Funding Source: Karius™

Amount: \$114,872

Submission date: July 2021

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigators: Ajay Bharti, M.D.

*TITLE: WEIGHT TRENDS IN PERSONS LIVING WITH HIV AFTER SWITCHING OFF INTEGRASE STRAND TRANSFER INHIBITOR BASED REGIMENS

Funding Source: Janssen Pharmaceuticals, Inc.

Amount: \$433,705

Submission date: June 2021

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigators: Jeffrey Yin, Pharm.D, Lucas Hill, Pharm.D.

*TITLE: INCIDENCE & PREDICTORS OF LARGE WEIGHT GAIN AMONG RECIPIENTS OF INTEGRASE INHIBITORS: WHAT AMOUNT OF WEIGHT GAIN PREDICTS HOSPITALIZATIONS?

Funding Source: Gilead Sciences

Amount: \$405,524

Submission date: June 2021

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigators: Jeffrey Yin, Pharm.D, Lucas Hill, Pharm.D.

*TITLE: INCIDENCE OF C. DIFFICILE INFECTION BETWEEN FLUOROQUINOLONES AND CEFTRIAZONE/AZITHROMYCIN AMONG HOSPITALIZED VETERANS AFFAIRS PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA.

Funding Source: Paratek Pharmaceuticals.

Amount: \$60,458

Submission date: November 2019

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

*TITLE: REAL-WORLD USAGE AND CLINICAL OUTCOMES ASSOCIATED WITH LETERMIVIR IN ALLOGENEIC HCT PATIENTS AT HIGH RISK FOR CMV REACTIVATION.

Funding Source: Merck & Co, Inc.

Amount: \$172,508

Submission date: August 2019

Role: Principal Investigator

Co-Investigator: Ila Saunders, Pharm.D.

*TITLE: EFFECTS OF ELBASVIR/GRAZOPREXIVIR ON RENAL AND METABOLIC OUTCOMES AMONG VETERANS' AFFAIRS PATIENTS WITH CHRONIC HEPATITIS C INFECTION.

Funding Source: Merck & Co, Inc.

Amount: \$76,977

Submission date: May 2017

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

*TITLE: A CROSSOVER STUDY TO ASSESS BIOEQUIVALENCE OF PHARMACOKINETIC PROFILES OF DARUNAVIR AND ETRAVIRINE WHEN COADMINISTERED WITH EITHER RITONAVIR OR COBICISTAT AMONG HEALTHY VOLUNTEERS

Funding Source: Janssen Pharmaceuticals

Amount: \$252,435.15

Submission date: June 2015
Role: Principal Investigator
Principal Investigator: Nimish Patel, Pharm.D., Ph.D.
Co-Investigator: Amit (Manjunath) Pai, Pharm.D.

*TITLE: BAREBACK AND SWINGING: DESCRIBING THE SOCIODEMOGRAPHIC CHARACTERISTICS OF A POPULATION AT HIGH RISK FOR SEXUALLY TRANSMITTED INFECTIONS

Funding Source: Society for the Scientific Study of Sexuality Student Research Grant
Amount: \$1,000

Submission date: February 2015

Role: Coinvestigator

Principal Investigator: Zachary Hecox

Co-Investigator: Nimish Patel, Pharm.D., Ph.D.

*TITLE: EFFECT OF ANTIRETROVIRAL REGIMEN TYPE ON VIROLOGIC OUTCOMES AMONG HUMAN IMMUNODEFICIENCY VIRUS INFECTED SUBSTANCE ABUSE PATIENTS

Funding Source: Gilead Research Scholars Program
Amount: \$115,852

Submission date: December 2014

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigator: Rodger MacArthur, M.D.

*TITLE: OPTIMIZING ANTIRETROVIRAL THERAPY AMONG HUMAN IMMUNODEFICIENCY VIRUS-INFECTED SUBSTANCE ABUSE PATIENTS

Funding Source: 2014 SIDP Young Investigator Research Award
Amount: \$10,000

Submission date: August 2014

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., Ph.D.

Co-Investigator: Bernadette Jakeman, Pharm.D.

*TITLE: COMPARING THE PREVALENCE OF POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN NS3/4A SERINE PROTEASE INHIBITORS AMONG VETERANS' AFFAIRS PATIENTS WITH HEPATITIS C MONOINFECTION

Funding Source: Vertex Pharmaceuticals, Inc.

Amount: \$39,071

Submission date: July 2013

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., M.S.

*TITLE: INCIDENCE AND PREDICTORS OF ACUTE MYOCARDIAL INFARCTION AMONG VETERANS AFFAIRS PATIENTS PREVIOUSLY TREATED WITH INTERFERON-BASED THERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION

Funding Source: Albany College of Pharmacy & Health Sciences

Award: Scholarship of Discovery Intramural Grant

Amount: \$5,000

Submission date: February 2012

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., M.S.

*TITLE: THE EFFECT OF ERYTHROPOEITIN STIMULATING AGENTS ON CLINICAL OUTCOMES AMONG VETERANS' AFFAIRS PATIENTS WITH CHRONIC HEPATITIS C INFECTION RECEIVING ANTIVIRAL THERAPY

Funding Source: American Society of Health-Systems Pharmacists

Award: 2012 New Investigator Grant

Amount: \$19,998

Submission date: January 2012

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., M.S.

Co-Investigator: Thomas Lodise, Pharm.D.

*TITLE: RELTATIONSHIP BETWEEN ANTIRETROVIRAL THERAPY PILL BURDEN AND SUSTAINED BLOOD PRESSURE CONTROL AMONG HIV-1 INFECTED PATIENTS

Funding Source: Gilead Sciences

Amount: \$41,055

Submission date: November 2011

Role: Principal Investigator

Principal Investigator: Nimish Patel, Pharm.D., M.S.

Co-Investigator: Christopher Miller, Pharm.D.

*TITLE: INCIDENCE AND OUTCOMES OF NEPHROTOXICITY AMONG VETERANS' AFFAIRS PATIENTS: A COMPARISON BETWEEN VANCOMYCIN AND LINEZOLID

Funding Source: Society of Infectious Diseases Pharmacists (SIDP)

Award: 2011 SIDP Young Investigator Research Award

Amount: \$10,000

Submission date: August 2011
Role: Principal Investigator
Principal Investigator: Nimish Patel, Pharm.D., M.S.
Co-Investigator: Thomas Lodise, Pharm.D.

*TITLE: EVALUATION OF KIDNEY INJURY MOLECULE – 1 (KIM-1) AMONG
VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS RECEIVING
ANTIRETROVIRAL TREATMENT

Funding Source: American Society of Health Systems Pharmacists (ASHP)
Award: 2011 Junior Investigator Research Grant
Amount: \$20,000

Submission date: February 2011
Role: Principal Investigator
Principal Investigator: Nimish Patel, Pharm.D., M.S.
Co-Investigators: Manjunath Pai, Pharm.D., Christopher Miller, Pharm.D.

TITLE: COMPARISON OF CLINICAL OUTCOMES BETWEEN PATIENTS
INFECTED WITH CA-MRSA and HCA-MRSA

Funding Source: Society of Infectious Diseases Pharmacists - Astellas Research Award:
Focus on Gram-Positive Resistance
Amount: \$20,000

Submission date: August 2008
Role: Co-Investigator
Principal Investigator: Thomas Lodise, Pharm.D.
Co-Investigators: Marc Scheetz, Pharm.D., Chao Qi, Ph.D.

Winter 2020

Therapeutics IV (SPPS 212D)

Course Co-Chair & Lecturer

Didactic Lectures (4 units: 62 PharmD students)

- HIV 6 hours
- Pre-Exposure Prophylaxis 1 hour
- Sexually Transmitted Infections 1 hour
- Pre-Exam Review 1 hour

Clinical Research Design & Application (SPPS 208)

Instructor & Lecturer

Small Group Facilitation & Didactic Lectures

- Journal club 2 hours
- Case control studies 1 hour

Fall 2019

Advanced Professional Practice I (SPPS 213A)

Small Group Facilitation & OSCE Evaluation

- OSCE on pain management 2 hours

Spring 2019

Therapeutics III (SPPS 212C)

Course Co-Chair & Lecturer

Didactic Lectures (6 units: 55 PharmD students)

- HIV 3 hour
- Pre-Exposure Prophylaxis 1 hour
- Sexually Transmitted Infections 1 hour
- Pre-Exam Review 2 hours

Winter 2019

Therapeutics II (SPPS 212B)

Lecturer

Didactic Lectures (6 units: 55 PharmD students)

- Tuberculosis 1 hour
- Skin and Skin Structure Infections 1 hour

Pharmacy Practice II (SPPS 202B)

Instructor

Small Group Facilitation & OSCE Evaluation

- Inhaler technique 2 hours
- OSCE on self-care pain/otic products 2 hours
- OSCE on self-care weight loss products 2 hours

Clinical Research Design & Application (SPPS 208)

Instructor

Small Group Facilitation

- Journal club 2 hours

Albany College of Pharmacy and Health Sciences (Albany, New York)

Fall 2018

Advanced Pharmacy Practice Experience

Clerkship (Precepted 2 students)

Antimicrobial Pharmacokinetic Monitoring Service
Stratton Veterans' Affairs Medical Center (Albany, New York)

Independent Study– Clinical Research Elective

Course coordinator

(Research Mentor, 2 students)

Summer 2018

Advanced Pharmacy Practice Experience

Clerkship (Precepted 1 student)

Antimicrobial Pharmacokinetic Monitoring Service
Stratton Veterans' Affairs Medical Center (Albany, New York)

Spring 2018

Applied Methods in Epidemiologic Research – Professional Elective

Course coordinator

(Research Mentor, 2 students)

Epidemiology Elective

Course Co-coordinator

Didactic Lectures (3 credits: 55 PharmD & graduate students)

- Causality 3 hours
- Overview of Study Designs 3 hours
- Case-Control Studies 3 hours

Pathophysiology, Therapeutics, Pharmacology & Medicinal Chemistry (PTP&M) – Infectious Diseases

Instructor

Didactic Lectures (4 credit course: >220 PharmD candidates)

- Sexually Transmitted Infections 1 hour
- Viral Hepatitis 2 hours
- ID cases 1 hour
- HIV 4 hours

Albany College of Pharmacy & Health Sciences (Albany, New York)

Applied Methods in Epidemiologic Research – Professional Elective

Course coordinator

(Research Mentor, 2 students)

Epidemiology II Elective

Team-Based Learning (3 credits: 35 PharmD students)

Summer 2016 **Advanced Pharmacy Practice Experience**

Clerkship (Precepted 6 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Spring 2016 **Advanced Pharmacy Practice Experience**

Clerkship (Precepted 3 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Applied Methods in Epidemiologic Research – Professional Elective

Course coordinator

(Research Mentor, 2 students)

Epidemiology Elective

Course Co-coordinator

Didactic Lectures (3 credits: 55 PharmD & graduate students)

- Causality 3 hours
- Overview of Study Designs 3 hours
- Case-Control Studies 3 hours

Pathophysiology, Therapeutics, Pharmacology & Medicinal Chemistry (PTP&M) – Infectious Diseases

Instructor

Didactic Lectures (4 credit course: >270 PharmD candidates)

- Sexually Transmitted Infections 1 hour
- Viral Hepatitis 2 hours
- ID cases 1 hour
- HIV 4 hours
- Opportunistic Infections 1 hours

Fall 2015

Advanced Pharmacy Practice Experience

Clerkship (Precepted 1 student)

Clinical Research elective

Albany College of Pharmacy & Health Sciences (Albany, New York)

Applied Methods in Epidemiologic Research – Professional Elective

Course coordinator

(Research Mentor, 2 students)

Epidemiology II Elective

Team-Based Learning (3 credits: 35 PharmD students)

Summer 2015

Advanced Pharmacy Practice Experience

Clerkship (Precepted 4 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Spring 2015

Advanced Pharmacy Practice Experience

Clerkship (Precepted 3 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Applied Methods in Epidemiologic Research – Professional Elective

Course coordinator

(Research Mentor, 2 students)

Epidemiology Elective

Course Co-coordinator

Didactic Lectures (3 credits: 55 PharmD & graduate students)

- Causality 3 hours
- Overview of Study Designs 3 hours
- Case-Control Studies 3 hours

Pathophysiology, Therapeutics, Pharmacology & Medicinal Chemistry (PTP&M) – Infectious Diseases

Instructor

Didactic Lectures (4 credit course: >270 PharmD candidates)

- Sexually Transmitted Infections 1 hour
- Viral Hepatitis 2 hours
- ID cases 1 hour

- HIV 4 hours
- Opportunistic Infections 2 hours

Independent Study – Clinical Research Elective

Course coordinator

(Research Mentor, 2 students)

Fall 2014

Applied Methods in Epidemiologic Research – Professional Elective

Course coordinator

(Research Mentor, 2 students)

Drug Interactions – Professional Elective

Instructor

Didactic Lectures (3 credit course)

- Drug interactions in HIV 3 hours

Independent Study – Clinical Research Elective

Course coordinator

(Research Mentor, 3 students)

Summer 2014

Advanced Pharmacy Practice Experience

Clerkship (Precepted 5 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Spring 2014

Advanced Pharmacy Practice Experience

Clerkship (Precepted 3 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Applied Methods in Epidemiologic Research – Professional Elective

Course coordinator

(Research Mentor, 2 students)

Epidemiology Elective

Course Co-coordinator

Didactic Lectures (3 credits: 25 PharmD & graduate students)

- Causality 3 hours
- Overview of Study Designs 3 hours
- Case-Control Studies 3 hours

Pathophysiology, Therapeutics, Pharmacology & Medicinal Chemistry (PTP&M) – Infectious Diseases

Instructor

Didactic Lectures (4 credit course: >270 PharmD candidates)

- Sexually Transmitted Infections 1 hour
- Viral Hepatitis 2 hours
- Tuberculosis 1 hour
- HIV 4 hours
- Opportunistic Infections 2 hours

Independent Study – Clinical Research Elective

Course coordinator

(Research Mentor, 4 students)

Fall 2013

Drug Information

Instructor

Didactic Lectures (4 credit course: >270 PharmD candidates)

- Study Design 2 hours

Independent Study – Clinical Research Elective

Course coordinator

(Research Mentor, 5 students)

Summer 2013

Advanced Pharmacy Practice Experience

Clerkship (Precepted 5 students)

Antimicrobial Pharmacokinetic Monitoring Service
Stratton Veterans' Affairs Medical Center (Albany, New York)

Spring 2013

Independent Study – Clinical Research Elective

Course coordinator

(Research Mentor, 4 students)

Advanced Pharmacy Practice Experience

Clerkship (Precepted 4 students)

Antimicrobial Pharmacokinetic Monitoring Service
Stratton Veterans' Affairs Medical Center (Albany, New York)

Epidemiology Elective

Course Co-coordinator

Didactic Lectures (3 credits: 40 PharmD & graduate students)

- Causality 3 hours
- Measures of Occurrence 3 hours
- Bias in Epidemiologic Studies 3 hours
- Overview of Study Designs 3 hours
- Cohort Studies 3 hours
- Case-Control Studies 3 hours

Pathophysiology, Therapeutics, Pharmacology & Medicinal Chemistry (PTP&M) – Infectious Diseases

Instructor

Didactic Lectures (4 credit course: >270 PharmD candidates)

- Sexually Transmitted Infections 1 hour
- Viral Hepatitis 2 hours
- Tuberculosis 1 hour
- HIV 4 hours
- Opportunistic Infections 2 hours
- Integrated Patient Cases 3 hours

Fall 2012

Independent Study – Clinical Research Elective

Course coordinator

(Research Mentor, 5 students)

Advanced Pharmacy Practice Experience

Clerkship (Precepted 4 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Summer 2012

Advanced Pharmacy Practice Experience

Clerkship (Precepted 2 students)

Independent Research Elective

Stratton Veteran's Affairs Medical Center (Albany, New York)

Spring 2012

Advanced Pharmacy Practice Experience

Clerkship (Precepted 3 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Advanced Pharmacy Practice Experience

Clerkship (Precepted 1 students)

Pharmacoepidemiology/Pharmacovigilance Elective

Stratton Veterans' Affairs Medical Center (Albany, New York)

Epidemiology Elective

Course Co-coordinator

Didactic Lectures (3 credits: 40 PharmD & graduate students)

- Causality 3 hours
- Overview of Study Designs 3 hours
- Case-Control Studies 3 hours

Independent Study – Clinical Research Elective

Course coordinator

(Research Mentor, 6 students)

Pathophysiology, Therapeutics, Pharmacology & Medicinal Chemistry (PTP&M) – Infectious Diseases

Course coordinator

Didactic Lectures (4 credit course: >270 PharmD candidates)

- Sexually Transmitted Infections 1 hour
- Viral Hepatitis 2 hours
- Upper Respiratory Infections 1 hour
- Influenza 1 hour
- Tuberculosis 1 hour
- HIV 4 hours
- Opportunistic Infections 2 hours

Fall 2011

Independent Study – Clinical Research Elective

Course coordinator

(Research Mentor, 6 students)

Summer 2011

Advanced Pharmacy Practice Experience

Clerkship (Precepted 4 students)

Antimicrobial Pharmacokinetic Monitoring Service

Stratton Veterans' Affairs Medical Center (Albany, New York)

Advanced Pharmacy Practice Experience

Clerkship (Precepted 2 students)

Pharmacoepidemiology/Pharmacovigilance Elective

Stratton Veterans' Affairs Medical Center (Albany, New York)

Advanced Pharmacy Practice Experience

Clerkship (Precepted 1 student)
Independent Research Elective
Albany Medical Center (Albany, New York)

Spring 2011

Advanced Pharmacy Practice Experience

Clerkship (Precepted 4 students)
Antimicrobial Pharmacokinetic Monitoring Service
Stratton Veterans' Affairs Medical Center (Albany, New York)

Advanced Pharmacy Practice Experience

Clerkship (Precepted 1 student)
Independent Research Elective
Albany Medical Center (Albany, New York)

Epidemiology Elective

Course Co-coordinator
Didactic Lectures (3 credits: 40 PharmD & graduate students)

- Causality 3 hours
- Overview of Study Designs 3 hours
- Case-Control Studies 3 hours

Pathophysiology, Therapeutics, Pharmacology & Medicinal Chemistry (PTP&M) – Infectious Diseases

Didactic Lectures (4 credit course: >270 PharmD candidates)

- Sexually Transmitted Infections 1 hour
- Viral Hepatitis 2 hours
- Upper Respiratory Infections 1 hour
- Influenza 1 hour
- Tuberculosis 1 hour
- HIV 4 hours
- Opportunistic Infections 2 hours

Fall 2010

Independent Study – Clinical Research Elective

Course coordinator
(Research Mentor, 4 students)

Summer 2010

Advanced Pharmacy Practice Experience

Clerkship (Precepted 2 students)
Antimicrobial Pharmacokinetic Monitoring Service
Stratton Veterans' Affairs Medical Center (Albany, New York)

Advanced Pharmacy Practice Experience

Clerkship (Precepted 1 student)

Independent Research Elective

Albany Medical Center (Albany, New York)

Spring 2010

Pathophysiology, Therapeutics, Pharmacology & Medicinal Chemistry (PTP&M) – Infectious Diseases

Didactic Lectures (4 credit course: >200 PharmD candidates)

- Sexually transmitted infections 1 hour
- Viral Hepatitis 2 hours

Fall 2009

Pharmacotherapy III

Didactic Lectures (8 credit course: >200 PharmD candidates)

- Sexually transmitted infections 1 hour
- Tuberculosis 1 hour
- Urinary tract infections 1 hour
- Skin and skin structure infections 1 hour
- Osteomyelitis 1 hour
- Infective Endocarditis 1 hour

Drug Information

- Hypothesis Testing 1 hour
- Power and Sample Size 1 hour
- Study Design 1 hour

Summer 2009

Introductory Pharmacy Practice Experience

Clerkship (Precepted 2 students)

Patient Assessment – Clinical Pharmacokinetic Study

Hortense and Rubin Dialysis Center (Clifton Park, New York)

Advanced Pharmacy Practice Experience

Clerkship (Precepted 2 students)

Inpatient HIV

Albany Medical Center (Albany, New York)

Spring 2009

Independent Research Elective

(Research Mentor, 1 student)

Introductory Pharmacy Practice Experience

Clerkship (Precepted 2 students)
Patient Assessment – Clinical Pharmacokinetic Study
Hortense and Rubin Dialysis Center (Clifton Park, New York)

Advanced Pharmacy Practice Experience

Clerkship (Co-precepted 2 students)
Antimicrobial Pharmacokinetic Monitoring Service
Stratton Veterans' Affairs Medical Center (Albany, New York)

Fall 2008

Pharmacotherapy III

Didactic Lectures (8 credit course: >200 PharmD candidates)

- Sexually transmitted infections 1 hour
- Tuberculosis 1 hour
- Urinary tract infections 1 hour

Recitation Facilitator 5 hours

Drug Information

- Hypothesis Testing 1 hour
- Power and Sample Size 1 hour
- Study Design 1 hour

Seminar II

Course Co-coordinator

- Orientation to Seminar II 1 hour

Summer 2008

Advanced Pharmacy Practice Experience

Clerkship (Co-precepted 4 students)

- Inpatient HIV, Albany Medical Center
- Clinical Research Elective, ACPHS

Spring 2008

Pharmacotherapy IV

Recitation Facilitator 5 hours

Independent Research Elective

Research Mentor(2 students)

Fall 2007

Pharmacotherapy III

Didactic Lectures (8 credit course: >200 PharmD candidates)

- Sexually transmitted infections 1 hour
- Tuberculosis 1 hour

PROFESSIONAL SERVICE RESPONSIBILITIES

UNIVERSITY OF CALIFORNIA SAN DIEGO – SKAGGS SCHOOL OF PHARMACY & PHARMACEUTICAL SCIENCES

Service – Intramural

- 2020 – 2022 **Pharmacy Underrepresented Mentorship Program (PUMP)**
(Skaggs School of Pharmacy & Pharmaceutical Sciences)
Role: Member
- 2020 – present **Equity, Diversity and Inclusion Committee**
(Skaggs School of Pharmacy & Pharmaceutical Sciences)
Role: Member
- 2018 – present **Curricular and Programmatic Assessment Committee**
(Skaggs School of Pharmacy & Pharmaceutical Sciences)
Role: Member (2018-19), Vice-Chair (2019-20), Chair (2020-21)
- 2019 – present **Residency Research Council**
(UCSD Health)
Role: Mentor & Advisor

Service – Extramural, leadership positions in professional societies

- 2021 – present **American Academy of HIV Medicine - The Cesar Augusto Caceres Award for Technology in HIV Practice Selection Committee**
(Professional)
Role: Committee Member
- 2019 - present **American Academy of HIV Medicine – Pharmacist Committee**
(Professional)
Role: Committee Member
- 2019 – present **American College of Clinical Pharmacy – ID PRN Newsletter & Social Media Committee**
(Professional)
Role: Committee Member
- 2019 – present **American College of Clinical Pharmacy – HIV PRN Awards & Nominations Committee**

- (Professional)
Role: Committee Member
- 2019 – 2020 **Society of Infectious Diseases Pharmacists – Fundraising Committee**
(Professional)
Role: Committee Member
- 2018 – present **Society of Infectious Diseases Pharmacists – Recognitions Committee**
(Professional)
Role: Committee Member

ALBANY COLLEGE OF PHARMACY & HEALTH SCIENCES

Service – Intramural

- 2017 – 2018 **Post-Graduate Year 2 – Nephrology, Albany College of Pharmacy & Health Sciences – Longitudinal Clinical Research Rotation**
(Professional)
Role: Preceptor
- 2016 – 2017 **Scholarship of Teaching & Learning Certificate Program, Albany College of Pharmacy & Health Sciences**
(Departmental)
Role: Mentor
Mentee: Ryan Sangiovanni, Pharm.D., PGY-1 Stratton VAMC
- 2016 – 2018 **Assessment Committee, Albany College of Pharmacy & Health Sciences**
(School of Pharmacy & Pharmaceutical Sciences)
Role: Committee Member
- 2016 – 2017 **Faculty Search Committee, Albany College of Pharmacy & Health Sciences**
(Departmental)
Role: Chair
- 2012 – 2016 **Scholarship & Awards Committee, Albany College of Pharmacy & Health Sciences**
(College)

Role: Chair

- 2011 – 2013 **Faculty Search Committee, Albany College of Pharmacy & Health Sciences**
(Departmental)
Role: Committee Member
- 2011 – 2012 **Scholarship of Teaching & Learning Certificate Program, Albany College of Pharmacy & Health Sciences**
(Departmental)
Role: Mentor
Mentee: Neil Tierson, Pharm.D., PGY-1 Stratton VAMC
- 2010 – 2012 **Strategic Planning Scholarship Workgroup, Albany College of Pharmacy & Health Sciences**
(Departmental)
Role: Member
- 2010 – 2012 **Scholarship & Awards Committee, Albany College of Pharmacy & Health Sciences**
(College)
Role: Committee Member
- 2010 – 2011 **Continuing Education & Professional Development Committee, Albany College of Pharmacy & Health Sciences**
(College)
Role: Committee Member

Service – Extramural, leadership positions in professional societies

- 2017 – 2018 **Post-Graduate Year 2 – Pain Management, Stratton Veterans' Affairs Medical Center – Infectious Diseases Rotation**
(Professional)
Role: Preceptor
- 2013 – 2014 **Society of Infectious Diseases Pharmacists – Recognitions Committee**
(Professional)
Role: Chair
- 2013 – 2014 **Northeastern New York Chapter of the New York State Council of Health-Systems Pharmacists (NE-NYSCHP)**

- (Professional)
Role: President
- 2012 – 2013 **American Academy of HIV Medicine (AAHIVM)**
(Professional)
Role: Item writer for pharmacist credentialing exam
- 2012 – 2013 **Northeastern New York Chapter of the New York State Council
of Health-Systems Pharmacists (NE-NYSCHP)**
(Professional)
Role: President-Elect
- 2011 – present **Stratton Veterans Affairs Medical Center – Residency Preceptor
Committee**
(Professional)
Role: Consultant
- 2012 - 2013 **Society of Infectious Diseases Pharmacists – Recognitions
Committee**
(Professional)
Role: Vice-Chair
- 2011 – 2015 **Society of Infectious Diseases Pharmacists – Recognitions
Committee**
(Professional)
Role: Committee Member
- 2010 – 2012 **Society of Infectious Diseases Pharmacists – Research
Committee**
(Professional)
Role: Committee Member

Service – Extramural, peer reviewer for journals

- 2020 – present **Clinical Infectious Diseases**
(Professional)
Role: Journal Reviewer
- 2020 – present **Journal of International Medical Research**
(Professional)
Role: Journal Reviewer

- 2020 – present **Patient Preference and Adherence**
(Professional)
Role: Journal Reviewer
- 2019 – present **ACS Sensors**
(Professional)
Role: Journal Reviewer
- 2019 – present **Open Forum in Infectious Diseases**
(Professional)
Role: Journal Reviewer
- 2019 – present **Clinical Drug Investigation**
(Professional)
Role: Journal Reviewer
- 2019 – present **PharmacotherapyFirst**
(Professional)
Role: Book Reviewer
- 2019 – present **Vaccines**
(Professional)
Role: Journal Reviewer
- 2019 – present **Chemical Science**
(Professional)
Role: Journal Reviewer
- 2018 – present **Infectious Diseases and Therapy**
(Professional)
Role: Journal Reviewer
- 2018 – present **European Journal of Drug Metabolism and Pharmacokinetics**
(Professional)
Role: Journal Reviewer
- 2014 – present **Antimicrobial Agents and Chemotherapy**
(Professional)
Role: Journal Reviewer
- 2016 – present **BMC Public Health**
(Professional)
Role: Journal Reviewer

2016	Drug Safety (Professional) <i>Role: Journal Reviewer</i>
2016 - present	Therapeutic Advances in Infectious Disease (Professional) <i>Role: Journal Reviewer</i>
2016 – present	The Annals of Pharmacotherapy (Professional) <i>Role: Journal Reviewer</i>
2015 – 2018	Liver International (Professional) <i>Role: Journal Reviewer</i>
2015 - 2018	Medical Sciences (Professional) <i>Role: Journal Reviewer</i>
2014	BMC Infectious Diseases (Professional) <i>Role: Journal Reviewer</i>
2014 - present	AIDS Research and Human Retroviruses (Professional) <i>Role: Journal Reviewer</i>
2013 – 2014	American Society of Health-Systems Pharmacists Foundation (Professional) <i>Role: Residency Research Grant Reviewer</i>
2013 – present	Pharmacotherapy (Professional) <i>Role: Journal Reviewer</i>
2013 – 2020	Drugs of Today (Professional) <i>Role: Journal Reviewer</i>
2012 – 2016	Currents in Pharmacy Teaching and Learning Journal (Professional)

- Role: Journal Reviewer*
- 2010 - 2012 **Diagnostic Microbiology and Infectious Disease Journal**
(Professional)
Role: Journal Reviewer
- 2010 **American Journal of Health-Systems Pharmacists**
(Professional)
Role: Journal Reviewer

CERTIFICATIONS AND TRAINING

- American Academy of HIV Medicine credentialing (AAHIVP)
- ACCP Anticoagulation Traineeship – Anticoagulation Clinics of North America (ACNA)
- 2005 Paul Ambrose Scholar
- Centers for Disease Control & Prevention (CDC) Certified Smallpox Vaccinator
- CDC/American Pharmacists' Association Immunization Certificate Course
- APhA OTC Advisor Certificate Course
- National Institutes of Health – Principles of Pharmacology ClinPRAT Series

HONORS AND AWARDS

- 2019 **American College of Clinical Pharmacy – Outstanding Journal Reviewer**
Nominated by the Scientific Editors of *Pharmacotherapy* and Board of Directors of ACCP for both the quality and timely reviews
- 2019 **Janis V. Giorgi Memorial Award – California HIV/AIDS Research Program**
Award for new investigators and received the highest score on their first CHRP grant submission
- 2016 **American Society of Health-Systems Pharmacists Foundation: Student Research Award**
Roles: coauthor, statistician
- 2016 **Society of Infectious Diseases Pharmacists: Impact Paper of the Year Award**

- Roles: coauthor, statistician
- 2015 **Society of Infectious Diseases Pharmacists (SIDP) Young Investigator Award**
- 2012 **Preceptor of the Year**
Award based on nominations received by students on advanced pharmacy practice experiential clerkships
- 2012 **Outstanding Teacher of the Year**
Awarded by Student Government Association of ACPHS to recognize excellence in teaching
- 2009 **Society of Infectious Diseases Pharmacists: Impact Paper of the Year Award**
Role: coauthor
- 2009 **Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Infectious Diseases Fellows Grant Program**
- 2009 **Infectious Diseases Society of America – Fellows Travel Grant Recipient**
Awarded to infectious diseases fellows in recognition of excellence in abstract submission to the IDSA Annual Meeting
- 2006 **Lilly Achievement Award**
Awarded to an individual who has achieved scholastic success and manifested exceptional qualities of leadership and professional attitude
- 2006 **APhA-ASP Professionalism Award**
- 2005 **Association of Teachers of Preventive Medicine—Paul Ambrose Health Promotion Student Leader Micro-grant Recipient**
Awarded a micro-grant from ATPM to carry out an inter-professional immunization outreach project in the Capital District of New York State
- 2004 **New York State Council of Health-systems Pharmacists Leader in Pharmacy Award**

PROFESSIONAL ORGANIZATIONS

- American Academy of HIV Medicine
- American College of Clinical Pharmacy
- Infectious Diseases Society of America
- Phi Delta Chi Professional Pharmacy Fraternity
- Phi Lambda Sigma Professional Leadership Society
- Society of Infectious Diseases Pharmacists